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ABSTRACT 
 
XIAOMING YANG: Design, Synthesis, and Biological Studies of New 
Phenanthroindolizidine and Phenanthroquinolizidine Analogs as Anticancer Agents 
(Under the direction of Kenan Professor Kuo-Hsiung Lee) 
 
The overall goals of this research were to design and synthesize novel 
phenanthroindolizidine and phenanthroquinolizidine analogs, study corresponding structure-
activity relationships, and explore their potential mechanisms of action as a new class of 
anticancer agents. 
 A new series of phenanthrene-based tylophorine analogs was designed and 
synthesized, among which compounds 13, 19, 21, and 22 were found to have comparable 
or higher in vitro anticancer activity than previously reported analog PBT-1. Mechanistic 
studies suggested that these new analogs, like PBT-1, inhibit cancer cell growth through the 
inhibition of Akt phosphorylation and NF-κB signaling pathways.  
 In view of the scarcity of SAR research for this class of natural products, a new 
synthetic strategy was designed and established. An important characteristic of this method 
was preparation of the key intermediate 44 that can be used to generate a versatile pool of 
molecules possessing interesting anticancer profiles. The new methodology opened up an 
avenue to study SAR on the E-ring of these natural alkaloids. Compound 50c with a 7-
membered E-ring was synthesized for the first time and displayed greatly improved 
selectivity against A549 and HCT-8 cancer cell lines, suggesting a potential role of the E-ring 
size in determining potency. 
iv 
Based on the new synthetic approach, new derivatives with an opened E-ring or a 
heteroatom (N or O) incorporated in the E-ring were obtained. These new analogs still 
exhibited strong anticancer potency, and among them, compound 110 showed significant 
anticancer activity (average IC50’s around 20 nM) comparable with R-cryptopleurine. 
Compound 110 also exhibited improved cell-line selectivity, as well as increased polarity as 
predicted by BBB penetration ratio, which could potentially lead to reduced CNS toxicity. An 
in vivo study suggested that this compound had significant tumor growth inhibition against 
HT-29 human colorectal adenocarcinoma. 
 This improved synthetic methodology also allwed direct introduction of polar groups, 
such as hydroxyl and amino, at different positions in the E-ring of antofine and 
cryptopleurine. These proposed new derivatives should provide potentially useful 
information for SAR investigation and, most importantly, development of promising clinical 
trial candidate compounds. 
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CHAPTER 1 
CANCER AND CHEMOTHERAPY 
 
1.1 Introduction 
As a generic term, cancer refers to a large number of diseases, for which one 
important defining feature is the rapid creation of abnormal cells that can grow beyond their 
boundaries, invade adjoining parts of the body, and spread to other organs.1 WHO statistics 
indicated that cancer cases doubled between 1975 and 2000 globally, and will likely double 
again by 2020, and triple by 2030. Altogether, these diseases have long been a major cause 
of death worldwide and are projected to become the leading cause of death in 2010, 
according to the 2008 World Cancer Report.2 The high mortality of cancer and increasing 
rate of incidence have not only caused enormous torment to the bodies and minds of 
patients, but also imposed formidable financial burdens on individual families and society as 
a whole. 
 
1.2 Cause of cancer 
Cancer can be caused by many factors. Carcinogens (mutagens) can cause 
neoplasm by disrupting normal cellular physiology and generating errors in cells, which are 
then able to circumvent repair or apoptosis.3,4 These errors can accumulate and lead directly 
to cancer or be relayed to the following generation to be manifested, which is the hereditary 
cause of cancer.2,5 Research has also shown that under certain circumstances, cancer is 
caused by infection, including viral, such as human papillomavirus (cervical carcinoma), and 
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bacterial, such as Helicobacter pylori (gastric cancer).6 Additionally, some cancers are 
caused by hormonal imbalances and immune system dysfunction.7,8 
 
1.3 Treatment of cancer 
Current established and proposed approaches for treating cancer include local 
surgery for some solid tumors, radiotherapy, and chemotherapy (in its broadest sense: 
traditional chemotherapy using cytotoxic agents, targeted therapy, hormonal treatment, 
immunotherapy, and gene therapy).  
Before 1950, therapy remained primarily the venue of surgeons and involved 
excision of tumors.9 Later, radiotherapy became a valuable tool with the advent of the linear 
accelerator, artificial radionuclides such as cobalt 60, and brachytherapy, assisted by 
technological progress, e.g., computed tomography (CT) and magnetic resonance imaging 
(MRI) for the visualization of tumors.10 However, as both of the above therapies cannot 
eradicate metastatic cancers, another approach has evolved and become one of the most 
important weapons to treat cancer today – chemotherapy, i.e. using chemicals for 
intervention.11-14 
Although great progress has been made in prevention and treatment options, as well 
as understanding of the neoplastic processes, most cancers remain incurable.15 However, 
an ever expanding knowledge of cancer has now led to the wide acceptance and practice of 
cancer combination therapy, using multi-modality treatment choices (e.g., surgery plus 
radiotherapy or chemotherapy or both) to achieve the best clinical efficacy. Even within the 
same category, e.g. chemotherapy, this practice can be productive, as early studies showed 
that a combination of methotrexate (an antifolate), vincristine (a Vinca alkaloid), 6-
mercaptopurine, and prednisone (aka POMP regimen) could induce long-term remissions in 
children with acute lymphoblastic leukaemia (ALL). In addition, treatment with nitrogen 
mustard, vincristine, procarbazine, and prednisone (aka MOPP regimen) could cure patients 
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with Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.  However, combination 
chemotherapy achieved, at best, modest increases in response rates but conferred no 
survival advantage in metastatic melanoma and pancreatic cancers.16 
 
1.4 Cancer chemotherapy 
Cancer 
Chemo- 
therapy 
Classic  
chemotherapeutic  
agents 
Alkylating (-like) agents 
Nitrogen mustard analogs 
Alkyl sulfonates 
Ethylene imines 
Nitrosoureas 
Epoxides 
Other alkylating agents 
Platinum compounds 
Antimetabolites 
Folic acid analogs 
Purine analogs 
Pyrimidine analogs 
Topoisomerase inhibitors Type I topoisomerase inhibitors Type II topoisomerase inhibitors
Plant alkaloids and other 
natural products 
Vinca alkaloids and analogs 
Podophyllotoxin derivatives 
Colchicine derivatives 
Taxanes 
Other plant alkaloids and natural 
products 
Cytotoxic antibiotics and 
related substances 
Actinomycines 
Anthracyclines and related 
substances 
Other cytotoxic antibiotics 
Other 
Methylhydrazines 
Sensitizers used in 
photodynamic/radiation therapy 
Other antineoplastic agents 
Targeted therapy 
Monoclonal antibodies Bevacizamab (Avastin) etc. 
Small molecules Imatinib (Gleevec), Gefitinib (Iressa) etc. 
Hormonal therapy Adjuvant Tamoxifen etc. 
Immunotherapy 
Monoclonal antibody therapy Rituximab etc. 
Non-specific 
immunotherapies and 
adjuvants 
Interleukin-2 etc. 
Immunomodulating drugs Thalidomide etc. 
cancer vaccines No drugs approved by 2009 
Gene therapy - No drugs approved 
Table 1-1 Classification of cancer chemotherapy with representative drugs 
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Since Gilman and coworkers first introduced chemotherapy into clinical practice,16 
cancer chemotherapy has been expanding and developing at an unprecedented pace 
because of the explosion of knowledge in the field of molecular biology.  From a classical 
perspective, chemotherapeutic agents are cytotoxic compounds that interfere with cell 
division or DNA (RNA) synthesis and function; whereas, in a more comprehensive sense, 
they also include molecules that are designed to interfere with a specific molecular protein 
target that has a critical role in tumor growth or progression (Table 1-1).17 Table 1-1 includes 
the classifications of chemotherapeutic drugs that are commonly used in clinical 
practices.18,19 
 
1.5 Resistance of cancer to chemotherapy 
Despite the presently huge arsenal of agents available to treat cancers, they remain 
incurable in most cases. A predominant cause is the resistance, either intrinsic or acquired, 
of cancer cells to chemotherapeutic agents.20 
Two main groups of factors contribute to the development of drug resistance. One is 
related to drug metabolism and inadequate access of the drug to the target, and the other is 
cell- or tissue-specific factors, such as mutations or amplifications of genes or epigenetic 
alterations in signaling pathways that a drug uses to kill cancer cells. It has been recently 
pointed out that epigenetic changes can be a crucial driving force behind acquired drug 
resistance in cancer cells challenged with cytotoxic agents, which could arise early during 
the tumorigenesis process.21-23  
Most cancers are highly refractory, and all current therapeutic protocols prove to be 
only palliative rather than curative.  However, some tumor types, such as testicular cancer, 
gestational choriocarcinoma, Hodgkin’s disease and high-grade lymphoma, are highly 
sensitive to chemotherapy. High cure rates (>60%) can be achieved with chemotherapeutic 
regimens, and many patients become long-term survivors. P. Savage and T. Crook et al. 
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hypothesized that the curability of these malignancies results from an intrinsic “locked-in” 
state of sensitivity to proapoptotic stresses in these cells rather than properties of the drugs 
used to treat them.15 Thus, further exploration of why curable cancers evidently lack 
epigenetic plasticity and do not acquire resistance is of paramount importance to address 
how resistance could be managed. Moreover, another theory, the cancer stem cell 
hypothesis, states that many cancers contain a minority population of stem cells that can 
survive chemotherapy and reform a tumor offspring. However, this theory does not account 
for acquired resistance of all cells (not just stem cells) in some cancers after challenge with 
drugs.24,25 
 
1.6 Cancer prevention 
In recent years, another promising field in cancer treatment is cancer prevention, 
which is defined as active measures to decrease the incidence of cancer. Prevention might 
be accomplished through less contact with carcinogens (or modifying their metabolism), 
dietary supplementation, or chemoprevention (hormonal agents or vaccines). For instance, 
the COX-II inhibitior Celecoxib was found to decrease the incidence of various cancers in 
many animal models with no associated toxicity and is now the first selective COX-II inhibitor 
approved for the chemoprevention of colon cancer in patients with familial adenomatous 
polyposis, Soy consumption has also been associated with reduced risk of cancer, and in 
vitro and in vivo anticancer activity has been confirmed for one of its active ingredients, soy 
isoflavone genistein.26 Because of the non-toxic nature of chemopreventive agents and the 
fact that such agents used in combination are able to enhance anticancer activity of other 
chemotherapeutics and radiotherapy, chemoprevention (primary or secondary) has been 
increasingly recognized as a powerful tool to provide benefits for cancer patients.27 
 
6 
1.7 New promising drugs in clinical trials 
Class Target Example 
Kinases 
Receptor kinases
EGFR family BIBW-2992 
HGF and c-Met XL-880 
IGF pathway OSI-906 
Intracellular 
kinases 
c-Src AZD-0530 
PI3K/Akt/mTOR 
PI3K: PI-103 
Akt: Perifosine 
mTOR: Everolimus 
MAPK pathway 
Ras (FTI inhibitors): 
Tipifarnib 
Raf: RAF-265 
MEK: AZD-6244 
Tumor vasculature 
VEGF and VEGFR family Vatalanib 
Tubulin (VADs) 
Tubulin destabilizers: 
ZD-6126 
Flavanoids: DMXAA 
Epigenetic 
modulators 
DNMT Zebularine 
HDAC Belinostat 
Extracellular matrix Integrins Cilengitide 
Molecular chaperone HSP-90 Tanespimycin 
Ubiquitin-proteasome  Proteasome CEP-18770 
Direct apoptosis 
enhancers 
TRAIL AMG-655 (structure not shown) 
Survivin YM-155 
Bcl2 ABT-263 
Therapeutic 
sensitizers PARP AG-014699 
Mitotic kinase Aurora AZD-1152 KSP Ispinesib 
Table 1-2 Representative small-molecule therapeutics currently in clinical trials. (EGFR, epidermal 
growth factor receptor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; c-Src, cellular 
Src kinase; PI3K, phosphoinositide 3’-kinase; Akt, protein kinase B; mTOR, mammalian target of 
Rapamycin; MAPK, mitogen-activated protein kinase; Ras, rat sarcoma oncogenes; Raf, 
serine/theronine protein kinase; MEK, MAPK kinase; VEGF(R), vascular endothelial growth factor 
(receptor); VADs, vascular disrupting agents; DNMT, DNA methyltransferase; HDAC, histone 
deacetylase; HSP, heat shock protein; TRAIL, tumor necrosis factor (TNF) related apoptosis inducing 
ligand; Bcl2, B-cell lymphoma proto-oncogene 2; PARP, poly(ADP-ribose) polymerase; KSP, kinesin 
spindle protein) 
 
Recently, research focus has shifted away from conventional chemically modified 
cytotoxic agents toward molecules that target certain signal pathways.  This shift has 
resulted partly from a failure to improve upon traditional cytotoxic chemotherapy and partly  
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Figure 1-1 Structures of representative drugs currently in clinical trials 
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from the increased understanding of the carcinogenesis process, from cancer cell 
proliferation, apoptosis, angiogenesis, invasion, to metastasis.28-31 At present, nearly one 
half of new drugs in clinical trials are angiogenesis inhibitors, while others target various 
points in different signaling pathways to inhibit cancer cell growth (Table 2 and Figure 1-1).32 
Another important class of drugs is monoclonal antibodies (MoAbs), some of which are also 
in clinical testing, such as anti-EGFR Cetuximab, c-Met inhibitor AMG-102, and CP-721 
(anti-IGF-1R receptor), etc.33 
 
1.8 Problems to be addressed 
Nowadays, unprecedented effort is being invested in exploring every single element 
of malignancies. Numerous accomplishments have been made, and yet more remains to be 
learned. Behind the giant halo of success in curing some cancers, several pivotal issues 
need to be addressed.  
One issue is how to accurately translate results from animal models to humans. 
Animal assays have become an important part of oncologic research to determine whether a 
compound is a good candidate for drug development. However, in most cases, they are 
poor predictors of clinical outcomes, because the biology and transformation processes in 
animals can differ significantly from those in humans.34 
A second issue is how to identify the subset of patients that can benefit the most 
from corresponding chemotherapy.35 A number of disappointing results have made it clear 
that grouping patients merely by histological type of cancers is insufficient. Reliable 
biomarkers using molecular or genomic tests for drug sensitivity are urgently needed to 
identify patients who are most likely to respond to certain drugs, so that the huge financial 
burden and unnecessary toxicity resulting from unresponsive treatment can be avoided.11 
9 
A third issue is how to optimally design trials to establish dosage, treatment 
schedules, and drug combinations, as well as monitoring of drug effects. In fact, a number of 
failures in clinical trials came partially from setting imperfect criteria for patient selection, 
protocols for medications, or plausible combinations of drugs.  For example, a phase III 
clinical trial was done using tariquidar (an inhibitor of P-glycoprotein) as an adjunctive 
treatment in combination with first-line chemotherapy for patients with non-small cell lung 
cancer (NSCLC); however, there was no strong evidence to suggest that P-glycoprotein is 
expressed to a significant extent in this cancer type.36 For patients who have a high risk of 
recurrence, effective design and launch of adjuvant trials are warranted, even though they 
can be expensive and time-consuming. 
A fourth issue is cancer resistance. Despite a seemingly grandiose list of available 
cancer drugs, in truth, we most often lose against most cancers. This failure happens 
because certain cancers become resistant after one or two rounds of drug treatment. 
Therefore, an improved understanding of the molecular changes that lead to resistance will 
assist in adjusting treatment accordingly and determining what measures should be taken to 
counteract any adverse alterations.  
In the near future, we look to see a great number of new drugs enter the clinical 
practice, and patients can expect more survival benefit from these new medications. 
However, this outcome will only be accomplished by a great multi-disciplinary effort. Striving 
to find more chemical entities with novel anticancer mechanisms will undoubtedly accelerate 
this process and we hope, not far ahead, cancers can be treated as chronological diseases, 
and cure will no longer be just a dream. 
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CHAPTER 2 
PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE 
ALKALOIDS 
2.1  Introduction 
Phenanthroindolizidine and phenanthroquinolizidine alkaloids are a series of natural 
products primarily found in two plant species: the Asclepiadaceae family, including five 
genera Tylophora, Cyanchum, Vincetoxzcum, Pergularza and Antitoxzcum, and the 
Moraceae family (the genus Ficus), which spread over Africa, Asia, Australia and the Pacific 
Islands.1 The leaves of these plants have long been used to treat asthma, bronchitis, 
rheumatism, and dysentery. This early application as herbal medicine sparked the isolation 
and identification of primary therapeutic ingredients from these plants, which led to the 
discovery of over 60 structurally related alkaloids.2,3 This class of natural products is 
normally pentacyclic with a phenanthrene ring conjugated with an indolizidine or 
quinolizidine moiety. A chiral center is commonly seen at the C13a or C14a position (Figure 
2-1). The first isolation of one of its members, tylophorine, was reported in 1935 from 
Tylophora indica.4 In 1960, its structure was reported to have an S configuration that later 
was revised to R, based on total synthesis and measurement of optical rotation.5  
 
2.2  Pharmacological activities and possible mechanism of actions 
Phenanthroindolizidines and phenanthroquinolizidines have been found to display 
numerous interesting pharmacological activities, such as antimicrobial (anti-ameobic, 
antiviral, antibacterial, and antifungal), anti-inflammatory, anti-angiogenic, and most notably, 
14 
anticancer activity. However, the specific target(s) of these natural products remain(s) 
unknown, while more and more evidence has indicated that multiple targets might be 
present for these alkaloids in vivo. 
     
Figure 2-1 Representative phenanthroindolizidines and phenanthroquinolizidines 
 
2.2.1 Antimicrobial activities (antiameobic, antiviral, antibacterial, and antifungal)  
Recent studies have shown that tylophorine B (antofine) exhibited 60% inhibition of 
tobacco mosaic virus (TMV) at a concentration of 10-6 g/ml, in contrast to a commercial 
antiviral agent DHT (2,4-dioxohexahydro-1,3,5-triazine), which exhibited only 50% inhibition 
at 5×10-4 g/ml under the same conditions. Considering that TMV assembly begins with 
specific recognition by the coat protein aggregate of oriRNA, and that tylophorine B interacts 
favorably with oriRNA, Xi et al. speculated that tylophorine B possibly exerts its virus 
inhibition by binding to oriRNA and interfering with virus assembly initiation.6,7 In addition, 
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Baumgartner et al. found that racemic antofine isolated from F. septica displayed significant 
antibacterial and antifungal activities against B. subtilis, E. coli, M. luteus, and P. oxalicum at 
a comparable level as tetracycline hydrochloride and miconazole nitrate.8 Bhutani K. et al. 
reported that phenanthroindolizidine alkaloids showed interesting antiamoebic activity.9  
 
2.2.2 Anti-inflammatory activity 
From early in vitro and in vivo assays showing the interesting anti-inflammatory 
effects of tylophorine to today’s comprehensive research in terms of the underlying 
mechanism, numerous studies have established the notable anti-inflammatory features of 
phenanthroindolizidine and phenanthroquinolizidine alkaloids. In fact, the anti-inflammatory 
effects of these natural products have been exploited for many years, as ancient people 
used leaves and roots of plants (e.g., T. indica or F. septica) containing these alkaloids to 
treat inflammation-related diseases, such as asthma, bronchitis, and rheumatic disorders, 
etc.3 
Yang et al. reported that tylophorine and 7-methoxycryptopleurine potently 
suppressed lipopolysaccharide (LPS)/interferon γ (IFNγ)-induced production of nitric oxide in 
RAW264.7 cells and that tylophorine inhibited the induced protein levels of tumor necrosis 
factor α (TNFα), inducible nitric-oxide synthase (iNOS), and cyclooxygenase (COX-II).10,11 In 
addition, NO production was inhibited by antofine at a concentration less than 5 nM.12 
Furthermore, tylophorine was able to block the activation of NF-κB and AP-1, indicating that 
it might exert its anti-inflammatory effects by inhibiting the expression of proinflammatory 
factors and related signaling pathways.13 Choi et al. found that a tylophorine derivative, 
DCB-3503, caused significant abrogation of skin disease in MRL/Faslpr mice and might have 
a role in the treatment of inflammatory skin disease in systemic lupus erythematosus 
(SLE).14 
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2.2.3 Anti-angiogenic activity 
One group from Australia found that C8c-C15 monoseco analogs of cryptopleurine 
and julandine exhibited anti-angiogenic activity. Most of the monoseco analogs showed 
100% inhibition of blood vessel growth at 100 μg/ml, and two analogs showed full inhibition 
even at 10 μg/ml. However, these monoseco analogs showed significantly reduced 
cytotoxicity (Figure 2-3). These monoseco compounds structurally resemble combretastain 
A, a potent inhibitor of cell growth, tubulin polymerization, and angiogensis currently in 
clinical trials. Thus, it was speculated that monoseco analogs of cryptopleurine and julandine 
might act in a similar mode as combretastain A, by binding to tubulin in newly formed 
endothelial cells lining the tumor vasculature.15  
 
2.2.4 Anti-cancer activity 
The most exciting finding regarding the therapeutic potential of this compound class 
came from a National Cancer Institute (NCI) anticancer screening program using 60 cancer 
cell lines, which demonstrated that tylophorine and its analogs can significantly inhibit 
cancer cell growth with an average GI50 around 10-8 M (Table 2-1).16 More interestingly, 
recent studies have shown that tylophorine analogs exhibit potent cytotoxic activity against a 
broad range of human cancer cells and sublines resistant or cross-resistant to various 
conventional anticancer drugs, such as etoposide, paclitaxel, topotecan, adriamycin, 
cytosine arabinoside, gemcitabine, hydroxyurea, or camptothecin. Tylophora alkaloids do 
target the NF-κB signaling pathway,17 an important machinery of drug resistance acting 
through anti-apoptosis and regulation of p-glycoprotein, which is another well-known 
mechanism of multidrug resistance to chemotherapy. Therefore, these alkaloids might have 
a novel mechanism of anticancer action.17 Consequently, these natural products have been 
explored extensively to understand how they are functioning to kill cancer cells. However, 
17 
until now, no specific protein or nucleic acid target has been identified in terms of their 
significant cytotoxicity.  
Compound Cell linea GI50 (M) 
(-)-Cryptopleurine NCI panelb 1×10-12 
(-)-Antofine KB 1.5×10-8 
(-)-Tylophorine KB 1.7×10-8 
(-)-Ficuseptine C HepG2 and PANC-1 3.7×10-7 
Tylocrebrine NCI panel 2.95×10-8 
(+)-Tylophorinidine HepG2 and PANC-1 1×10-8 
(-)-Antofine-N-oxide KB 1.4×10-7 
Table 2-1 GI50’s of representative phenanthroindolizidines and phenanthroquinolizidines 
a Cell line: KB, human nasopharyngeal carcinoma (average), HepG2, human hepatocyte 
carcinoma, PANC-1, human pancreatic carcinoma. b Average GI50 for NCI 60-cell line panel. c 
http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp 
Early studies suggested that some of these alkaloids arrest growth of cancer cells by 
inhibiting protein synthesis, as supported by the fact that the incorporation of leucine into 
protein was inhibited by 50% at a concentration of 2×10-8 M, 2×10-7 M, 1×10-6 M for 
cryptopleurine, tylocrebrine and tylophorine, respectively.18 But incorporation of uracil into 
nucleic acids in Ehrlich ascites-tumor cells was not inhibited at 10-5 M. In addition, Huang et 
al. found that tylocrebrine irreversibly inhibits protein biosynthesis in HeLa cells and rabbit 
reticulocytes. In HeLa cells, protein, DNA, and RNA synthesis were inhibited by 95%, 75% 
and 60%, respectively, by tylocrebine at a concentration of 300 nM. In contrast to effects on 
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DNA synthesis, inhibition of RNA synthesis was readily reversible. The primary effect of 
tylocrebrine on protein synthesis is thought to be on chain elongation.19 
By utilizing mutants of CHO cells cross-resistant to the protein synthesis inhibitors 
emetine, cryptopleurine, and tylocrebrine, Gupta et al. found that these three compounds, as 
well as tubulosine, might share a common site of action, which was believed to be the 40S 
ribosomal subunit. This conclusion was also strongly supported by the failure of EmtR 
(emetine resistant), TylR, and CryR mutants to complement each other in somatic cell hybrids. 
It was further pointed out that some of the similarities in their structures might constitute the 
active determinant of these compounds and be responsible for their biological activity.20-23 
Dolez et al. also demonstrated that a single binding site with high affinity for [14a-
3H]cryptopleurine exists for both 80S ribosomes and 40S ribosomal subunits. In addition, 
40S, 60S, 70S, and 80S ribosomal species were found to have multiple binding sites with 
low affinity for this compound, which could account for the inhibition of peptide bond 
formation that is observed at high cryptopleurine concentrations.24 
Besides these findings, some other potential targets of these alkaloids have been 
reported, for example, hypoxia-inducible factor 1 (HIF-1). This postulate is based on the fact 
that R-cryptopleurine and 15R-hydroxycryptopleurine potently inhibit hypoxic activation of 
HIF-1 in the AGS human gastric cancer cell line (IC50 8.7 nM and 48.1 nM, respectively), by 
blocking the accumulation of HIF-1α subunit without effects on the expression of HIF-1β.25 
Because overexpression of HIF-1α is related to poor prognosis in a large number of cancers, 
HIF-1 has been an important target of cancer chemotherapy. Furthermore, Rao and 
Venkatachalam et al. reported that thymidylate synthase (TS), a key target enzyme for 
cancer chemotherapy, which provides precursors for DNA biosynthesis through a de novo 
pathway, was potently inhibited by tylophorinidine in two types of leukemias, chronic 
myelocytic leukemia and acute lymphocytic leukemia (IC50=50 µM). They also found that 
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dihydrofolate redutase (DHFR) activity was significantly inhibited with an IC50 value of 32 µM. 
Concentrations greater than 75-95 µM resulted in a complete loss of DHFR activity, and the 
inhibition was slow and reversible, as a simple linear “non-competitive” type.26-28 
 
Figure 2-2 Structure of DCB-3503 
Gao et al. found that S-tylophorine and its analog (DCB-3503, Figure 2-2), might 
have a novel mode of antitumor action, in contrast to most current antitumor 
chemotherapeutic drugs that exert their action by induction of DNA breaks, inhibition of DNA 
synthesis, or perturbation of tubulin function. Data suggested that tylophorine and its analog 
do not induce p53 expression and apoptosis in HepG2 cells. However, interestingly, they did 
have dose dependent inhibitory effects on three signaling pathways: activator protein-1 (AP-
1), cAMP response element (CRE), and NF-κB. NF-κB was the most sensitive, with an IC50 
value of 30 nM for tylophorine and 100 nM for DC3503, in contrast to 500 nM for both 
compounds on the AP-1 and CRE pathways. In addition, a number of cell cycle regulatory 
proteins, such as cyclin D1, cyclin B1, CDK1, CDK2, and CDK4, were all affected by DCB-
3503, which suppressed the expression of these proteins.17 The authors pointed out that 
these structurally similar alkaloids and their derivatives should not necessarily be considered 
as the same class of compounds, because their individual mechanisms might be quite 
different.29 All of the above findings suggested that these natural alkaloids might have 
multiple targets in vivo, leading to the possibility that they function by interfering with various 
stages of cell growth.  
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2.3 Toxicity of phenanthroindolizidines and phenanthroquinolizidines 
Although these natural alkaloids possess strong anticancer activity in vitro, most of 
them are generally toxic against the central nervous system (CNS). Although early studies 
with cryptopleurine showed 50% inhibition of tumor growth in mice transfected with Ehrlich 
ascites tumor cells during a period of ten days at a dose of 3 μM/kg twice daily, later NCI 
studies found this compound to be generally toxic.18 Tylocrebine, which has shown some 
promising anticancer results in vivo, failed Phase I clinical trial due to CNS toxicity, 
manifested as disorientation and ataxia.30 R-Tylophorine was non-toxic up to 500 mg/kg in 
rats, but only 60 mg/kg in hamsters. However, at high doses, some CNS toxicities such as 
ptosis, sedation, decreased motor activity, and staggering gait, were observed in rats.31 In 
summary, these potential CNS toxicities have limited the development and use of 
tylophorine alkaloids as safe and efficacious anticancer candidates. However, it has been 
proposed that chemical modification with polar groups could help reduce such CNS toxicity 
by decreasing blood-brain barrier penetration. This objective is one of the primary goals of 
my current study.30 
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CHAPTER 3 
DESIGN, SYNTHESIS, AND SAR STUDY OF NEW PHENANTHRENE-
BASED TYLOPHORINE ANALOGS 
 
3.1 Introduction 
In previous studies, our group discovered a series of interesting tylophorine analogs 
known as phenanthrene-based tylophorine (PBT) derivatives, which displayed potent 
anticancer activity.1-3 The PBT structure features an opened D-ring, while the E-ring is 
connected to the phenanthrene scaffold with a methylene bridge. Many substituents were 
introduced into the E-ring at different positions in order to obtain detailed SAR data for lead 
optimization. Through these efforts, PBT-1, which has a 4’-hydroxymethyl piperidine moiety 
(Figure 3-1), was found to be the most active among these compounds against four types of 
human cancer cell lines, including multi-drug resistant (MDR) KB-VIN cells.  
 
 
Figure 3-1 Structures of R-(-)-antofine, S-(+)-tylophorine, and PBT-1 
 
Further mechanistic studies demonstrated that PBT-1 inhibits cancer cell growth 
through the inhibition of Akt phosphorylation and NF-κB activity. However, NF-κB was not 
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inhibited through the canonical signaling pathway, but by non-classical signal transduction 
involving IKKα and NF-κB subunit RelB.4  
In vivo testing using a xenograft model of human lung tumor cells in mice showed that 
24b (PBT-1 hydrochloride, 10 mg/kg) inhibited cancer cell growth significantly from day 1 to 
day 5 and moderately from day 9 to 29 without any changes in body weight and overt 
toxicity (Figure 3-2).3 These interesting results have prompted us to make further 
modifications using PBT-1 as a lead in order to elevate its anticancer activity. 
 
Figure 3-2 Tumor growth curves in SCID mice treated with PBT-1 
 
3.2 Design and synthesis of new PBT analogs 
3.2.1 Design  
 
Figure 3-3 Design of new PBT analogs 
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Previous studies showed that a bulky functionality on the attached piperidine or pyrrole 
ring resulted in decreased anticancer activity. Therefore, in the new PBT series, substituents 
that are similar in size to the hydroxymethyl group of PBT-1 were introduced and compared. 
In addition, in consideration of unwanted CNS toxicity, polar groups such as amino and 
hydroxy groups were considered (Figure 3-3). Regarding the substituent position, prior 
studies focused mainly on the C2’ and C4’ positions; thus, we also placed substituents at 
C3’ for a more thorough SAR investigation.   
 
3.2.2  Chemistry 
The synthesis of these new PBT analogs is shown as follows (Scheme 3-1).5 
Scheme 3-1. Reagents and conditions: (a) CH3I, NaHCO3, DMF, overnight; (b) LiAlH4, THF, r.t.; (c) 
PBr3, CH2Cl2, 0 °C; (d) 3- or 4-substituted piperidine, DMF, TEA or K2CO3, 60 °C, 4h; (e) 2N HCl, 
MeOH, r.t.; (f) MsCl, pyridine, r.t., 16h 
 
The phenanthrene-9-carboxylic acid 1, obtained via three steps as reported in the 
literature,6 was reacted with methyl iodide using sodium bicarbonate to afford the methyl 
ester 2, which was then reduced with LiAlH4 at room temperature to give the alcohol 3, 
followed by bromination using tribromophosphine in dichloromethane. For the final step, the 
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bromine atom of 4 was displaced by various substituted piperidines at room temperature or 
60 °C to afford target products. The Boc group was removed with HCl in MeOH and 
sulphonylation was carried out in CH2Cl2. The ketone moiety was reduced with LiAlH4 to 
form the corresponding alcohol in excellent yields.  
 
3.3  Results and discussion 
3.3.1 Anticancer activity of new PBT analogs 
Through the above synthetic pathway, a total of 19 new PBT analogs were 
synthesized and tested against a panel of four cancer cell lines, KB (nasopharyngeal), A549 
(lung), DU-145 (prostate), and KB-VIN (an MDR KB subline), using antofine as control. The 
screening results are shown in Table 3-1. 
 
Compd R IC50 (μM) KB KBvin A549 DU145 
5 0.73 0.84 0.62 0.82 
6 1.11 1.30 1.19 1.09 
7 13.85 18.09 14.58 17.23 
8 8.69 8.87 8.80 9.60 
9 0.86 1.06 0.88 0.93 
10 0.55 0. 66 0.36 0.28 
11 9.30 7.48 6.57 12.56 
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12 1.12 1.15 0.88 1.10 
13 0.11 0.14 0.11 0.11 
14 1.26 1.97 1.38 1.85 
15 0.66 1.08 1.02 1.02 
16 1.94 3.04 1.86 2.68 
17 1.30 1.42 1.30 1.50 
18 0.26 - 0.49 0.35 
19 0.08 - 0.08 0.11 
20 0.83 - 0.80 1.07 
21 0.18 - 0.13 0.16 
22 0.18 - 0.18 0.26 
23 0.90 - 0.56 0.84 
PBT-1 0.18 0.21 0.18 0.24 
Antofine - 0.036 0.025 0.022 0.025 
Table 3-1 In vitro anticancer activity of new PBT analogs 5-23 
 
3.3.2  SAR of new PBT analogs 
Most compounds exhibited significant activity, with 13 and 19 showing the highest 
potency with IC50 values in the 0.08-0.14 μM range. Changing the position of the 
hydroxymethyl substituent from C-4’ in PBT-1 to C-3’ in 21 and 22 did not affect the potency; 
all three compounds had similar IC50 values. The stereochemistry of the side chain in the 
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latter two compounds also had little effect on potency. However, compound 19 was ca. two-
fold more active compared with PBT-1, as indicated by lower IC50 values (0.08-0.11 
compared with 0.18-0.24 μM). Because 19 has a 4’-hydroxyl rather than 4’-hydroxymethyl 
substituent on the piperidine ring, the augmented efficacy might be explained by a better fit 
into the binding pocket and better interaction with the target groups, possibly through 
hydrogen bonding with the oxygen atom at the C-4’ position (directly or indirectly).  
Interestingly, compound 13, the oxidized form of 19, possessed similar, high potency, 
indicating that the oxygen atom could be used primarily as a hydrogen bond acceptor, as 
long as the spatial distance is favorable, while a possible covalent adduct (to the ketone) is 
less likely to be formed. However, when the oxo group was at the C-3’ rather than C-4’ 
position (20 vs. 13), the inhibitory potency decreased by about eight-fold, possibly indicating 
less optimal hydrogen bonding with the target in the binding pocket. Potency decreased 
even more when a methyl ester was present at C-3’ in addition to an oxo group at C-4’ 
(compare 14 and 13).  In fact, compound 14 showed the same potency as 16 and 17, which 
have only a methyl ester (cis and trans, respectively) at C-3’.  Thus, the oxygen atom at C-4’ 
in 14 might be displaced from its optimal hydrogen bonding angle as in 13, and thus, the oxo 
group might not be involved in binding. 
A lipophilic trifluoromethyl group at C-4’ (11) substantially decreased the inhibitory 
activity. Compound 12 with a cyano moiety at the same position showed significant activity, 
but was five- to ten-fold less potent compared with compounds containing an oxo (13), 
hydroxy (19), or hydroxymethyl (PBT-1) group, which might be associated with the oxidation 
state of nitrogen and particular orientation of its lone pair of electrons.  
Compound 18 (4’-CH2NH2.HCl) showed the greatest potency among the amino 
compounds, which exhibited IC50 values ranging from 0.26 to 0.49 μM. Compounds with the 
amino group present as the HCl salt showed uniformly better activity compared with their 
Boc-protected precursors, perhaps resulting from elevated water solubility and side chain 
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shortening after removal of Boc. However, the amine salts generally were less active than 
the corresponding compounds with a hydroxy group (PBT-1 vs. 18, 19 vs. 10, 22/23 vs. 5), 
suggesting that formation of a hydrogen bond alone cannot explain all interactions between 
these compounds and their targets. Compounds 5 (3’-CH2NH2) and 6 (3’-CH2NHBoc) 
showed significantly higher inhibition than 7 (3’-NH2) and 8 (3’-NHBoc), respectively. The 
extra methylene could put the hydrogen bond acceptor closer to the hydrogen bond donor in 
the binding pocket. Comparison of 9 (4’-NH-Boc or 4’-NHCO2t-Bu) and 15 (4’-NHSO2CH3) 
with 10 (4’-NH2.HCl) showed only moderate decreases in potency with the former two 
compounds, indicating that substitutions on the C4’-NH2 group did not significantly affect 
activity. 
 
3.4  Conclusions 
Through these efforts, 19 new PBT analogs were designed, synthesized, and tested 
against four cancer cell lines. Out of 19 compounds, four new molecules were found to have 
an improved or comparable level of cytotoxicity than PBT-1, with 13 and 19 being about two-
fold more potent.  
Compound Structure Predicted BBB penetration  (C.brain/C.blood) 
PBT-1 0.087 
13 0.020 
19 0.041 
21 or 22 0.089 
Table 3-2 Prediction of BBB penetration for PBT-1, 13, 19, 21, and 22 
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A blood-brain penetration ratio was then predicted for these four new derivatives in 
comparison with PBT-1; the results are shown in Table 3-2.7 Both 13 and 19 have a lower 
predicted BBB penetration ratio than PBT-1, while 21 and 22 are comparable to PBT-1. As 
PBT-1 has been shown to have no toxicity in a mouse model, it is foreseeable that these 
four new analogs would have no overt toxicity as well, based on the predicted BBB 
penetration ratios and structural similarity. 
 
3.5  Experimental section 
3.5.1  Chemistry 
Materials and Methods. Melting points were measured with a Fisher Johns melting 
apparatus without correction. 1H NMR spectra were measured on a 300 MHz Varian Gemini 
2000 spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Mass spectra were measured on a Shimadzu LC-MS2010 instrument. Thin-layer 
chromatography (TLC) and preparative TLC were performed on precoated silica gel GF 
plates purchased from Merck, Inc. Biotage Flash+ or Isco Companion systems were used 
for flash chromatography. Silica gel (200-400 mesh) from Aldrich, Inc. was used for column 
chromatography. All other chemicals were obtained from Aldrich, Inc., and Fisher, Inc. 
2,3-Methylenedioxy-6-methoxyphenanthrene-9-carboxylic acid methyl ester (2): 
The carboxylic acid 1 (1.16 g, 3.92 mmol) was suspended in 30 mL of DMF, to which 
NaHCO3 (527 mg, 6.27 mmol) and CH3I (0.49 mL, 7.80 mmol) were added. The mixture was 
stirred overnight at room temperature before 20 mL of water was added to quench the 
reaction. EtOAc was used for extraction. The organic layers were collected and washed with 
water and brine, dried over MgSO4. The methyl ester 2 was used in the next step without 
further purification (quantitative). 1H NMR (300 MHz, CDCl3): δ 8.27 (d, J = 9.30 Hz, 1H), 
7.90 (s, 1H), 7.81 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.22 (dd, J = 9.00 Hz, J = 2.40 Hz, 1H), 
7.16 (s, 1H), 6.10 (s, 2H), 4.00 (s, 3H), 3.90 (s, 3H); ESI MS m/z 310.95 (M+H)+. 
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2,3-Methylenedioxy-6-methoxy-9-hydroxymethyl-phenanthrene (3): The ester 2 
(500 mg, 1.61 mmol) in 30 mL THF was added to LiAlH4 in 20 mL THF in an ice bath, and 
the mixture was then stirred at room temperature for 2 h. Five mL of water and 5 mL of 2N 
NaOH were added and the mixture was filtered. The solvent was removed under vacuum, 
and the residue was redissolved in CH2Cl2, washed with brine and dried over MgSO4. The 
product 3 was used without further purification. 1H NMR (300 MHz, CDCl3): δ 8.26 (d, J = 
9.30 Hz, 1H), 7.88 (s, 1H), 7.81 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 
2.40 Hz, 1H), 7.15 (s, 1H), 6.09 (s, 2H), 4.96 (s, 2H), 4.01 (s, 3H); ESI MS m/z 283.00 
(M+H)+. 
2,3-Methylenedioxy-6-methoxy-9-bromomethyl-phenanthrene (4): At 0 °C, PBr3 
(1.18 mL, 12.56 mmol) was added dropwise to 3 (885 mg, 3.14 mmol) in CH2Cl2. The ice 
bath was then removed and the mixture was stirred at room temperature for 3 h before 20 
mL sat. NaHCO3 was added. The mixture was extracted using CH2Cl2, washed with brine, 
and dried over MgSO4. Chromatography gave 700 mg product (65%). 1H NMR (300 MHz, 
CDCl3): δ 8.30 (d, J = 9.30 Hz, 1H), 7.87 (s, 1H), 7.79 (d, J = 2.40 Hz, 1H), 7.39 (s, 1H), 
7.22 (dd, J = 9.00 Hz, J = 2.40 Hz, 1H), 7.15 (s, 1H), 6.08 (s, 2H), 4.68 (s, 2H), 4.00 (s, 3H); 
ESI MS m/z 346.05 (M+H)+. 
General procedure for the synthesis of 9-substituted phenanthrene. Substituted 
piperidine (in excess) was added to a mixture of bromide and TEA in DMF, which was 
stirred at room temperature or 60 °C overnight. DMF was then removed under reduced 
pressure, and CH2Cl2 was used for extraction. The organic layers were combined, 
sequentially washed with 1N HCl, sat. NaHCO3 and brine, and dried over MgSO4. 
Chromatography afforded the final products (Yield: 50%-90%). HCl salt was prepared using 
2M aqueous HCl in MeOH at room temperature. 
(R/S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-aminomethyl-
piperidine hydrochloride (5): 1H NMR (300 MHz, CDCl3): δ 8.28 (d, J = 9.00 Hz, 1H), 7.90 
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(s, 1H), 7.80 (d, J = 2.40 Hz, 1H), 7.39 (s, 1H), 7.22 (dd, J = 9.00 Hz, J = 2.40 Hz, 1H), 7.16 
(s, 1H), 6.08 (s, 2H), 4.00 (s, 3H), 3.81 (m, 2H), 2.95-2.88 (m, 1H), 2.82-2.80 (m, 1H), 2.57 
(d, J = 6.30 Hz, 2H), 2.10-2.04 (m, 2H),  1.94 (m, 2H), 1.75 (m, 2H), 1.01 (m, 1H); ESI MS 
m/z 379.10 (M+H)+. Anal. (C23H26N2O3•2HCl•2H2O) C, N, O, 
(R/S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-N-Boc-
aminomethyl-piperidine (6): 1H NMR (300 MHz, CDCl3): δ 8.31 (d, J = 9.00 Hz, 1H), 7.91 
(s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.39 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 2.40 Hz, 1H), 7.16 
(s, 1H), 6.09 (s, 2H), 4.46 (s, 1H), 4.00 (s, 3H), 3.80 (m, 2H), 3.00 (m, 2H), 2.80 (m, 2H), 
2.10 (m, 2H), 1.89 (m, 2H), 1.62 (m, 2H), 1.38 (s, 9H), 1.05 (m, 1H); ESI MS m/z 479.15 
(M+H)+.  
(S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-N-Boc-
aminopiperidine (7): White solid; mp 133-135 °C; 1H NMR (300 MHz, CDCl3): δ 8.28 (d, J = 
8.70 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 
1.80 Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.44 (s, 1H), 4.01 (s, 3H), 3.86 (s, 2H), 2.54 (m, 2H), 
2.46 (m, 1H), 2.28 (m, 1H), 1.59 (m, 2H), 1.53 (m, 2H), 1.44 (s, 9H), 1.26 (m, 1H); ESI MS 
m/z 465.15 (M+H)+.  
(S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-aminopiperidine 
hydrochloride (8): White solid; mp 265-267 °C; 1H NMR (300 MHz, CDCl3): δ 8.30 (d, J = 
9.00 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.42 (s, 1H), 7.22 (dd, J = 9.00 Hz, J = 
2.40 Hz, 1H), 7.16 (s, 1H), 6.09 (s, 2H), 4.00 (s, 3H), 3.90 (m, 2H), 2.88 (m, 1H), 2.75 (m, 
1H), 2.63 (m, 1H), 2.18 (m, 2H), 2.05 (m, 2H), 1.58-1.52 (m, 1H), 1.28 (m 1H); ESI MS m/z 
365.05 (M+H)+. Anal. (C22H24N2O3•2HCl•2H2O) C, N, O, 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-N-Boc-
aminopiperidine (9): White solid; mp 211-213 °C; 1H NMR (300 MHz, CDCl3): δ 8.29 (d, J = 
9.30 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.39 (s, 1H), 7.22 (dd, J = 9.00 Hz, J = 
2.70 Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.41 (s, 1H), 4.01 (s, 3H), 3.84 (s, 2H), 3.49 (m, 1H), 
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2.89 (m, 2H), 2.17 (m, 2H), 1.90 (m, 2H), 1.44 (s, 9H), 1.39 (m, 2H); ESI MS m/z 465.15 
(M+H)+.  
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-aminopiperidine 
hydrochloride (10): White solid; mp 261-263 °C; 1H NMR (300 MHz, CDCl3): δ 8.29 (d, J = 
9.00 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.40 (s, 1H), 7.22 (dd, J = 9.00 Hz, J = 
2.40 Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.01 (s, 3H), 3.84 (s, 2H), 2.93 (m, 2H), 2.72-2.63 
(m, 1H), 2.14-2.06 (m, 2H), 1.78 (m, 2H), 1.42-1.31 (m, 2H); ESI MS m/z 365.10 (M+H)+. 
Anal. (C22H24N2O3•2HCl•3H2O) C, N, O, 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-trifluoromethyl-
piperidine (11): White solid; mp 146-148 °C; 1H NMR (300 MHz, CDCl3): δ 8.25 (d, J = 9.00 
Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.39 (s, 1H), 7.26 (dd, J = 9.00 Hz, J = 2.40 
Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.01 (s, 3H), 3.85 (s, 2H), 3.05 (m, 1H), 2.05-2.01 (m, 
4H), 1.79 (m, 2H), 1.63 (m, 2H); ESI MS m/z 418.05 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-cyanopiperidine 
(12): White solid; mp 157-159 °C; 1H NMR (300 MHz, CDCl3): δ 8.23 (d, J = 9.00 Hz, 1H), 
7.91 (s, 1H), 7.81 (d, J = 2.70 Hz, 1H), 7.38 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 2.70 Hz, 1H), 
7.16 (s, 1H), 6.10 (s, 2H), 4.01 (s, 3H), 3.86 (s, 2H), 2.72 (m, 2H), 2.65 (m, 1H), 2.40 (m, 2H), 
1.90-1.79 (m, 4H); ESI MS m/z 375.05 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-piperidone (13): 
White solid; mp 161-163 °C;1H NMR (300 MHz, CDCl3): δ 8.32 (d, J = 9.30 Hz, 1H), 7.91 (s, 
1H), 7.82 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.21 (dd, J = 9.00 Hz, J = 2.70 Hz, 1H), 7.16 (s, 
1H), 6.09 (s, 2H), 4.01 (s, 3H), 3.97 (s, 2H), 2.83 (t, J = 6Hz, 4H), 2.44 (t, J = 6Hz, 4H); ESI 
MS m/z 364.05 (M+H)+. 
(R/S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-piperidone-3’-
carboxylic acid methyl ester (14): 1H NMR (300 MHz, CDCl3): δ 8.29-8.25 (d, J = 9.00 Hz, 
1H), 7.92 (s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.44 (s, 1H), 7.25-7.23 (m, 1H), 7.18 (s, 1H), 
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6.10 (s, 2H), 4.03-3.99 (s, 6H), 3.71 (s, 2H), 3.26-2.96 (m, 3H), 2.88-2.67 (m, 2H), 2.66-2.47 
(m, 1H), 2.39-2.35 (m, 1H); ESI MS m/z 422.00 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-methanesulfonyl-
amino-piperidine (15): White solid; mp 197-199 °C; 1H NMR (300 MHz, CDCl3): δ 8.24 (d, J 
= 9.00 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.40 (s, 1H), 7.19 (dd, J = 9.00 Hz, J 
= 2.40 Hz, 1H), 7.17 (s, 1H), 6.18 (m, 1H), 6.10 (s, 2H), 4.01 (s, 3H), 3.89 (s, 2H), 2.92 (m, 
3H), 2.28-2.21 (m, 2H), 1.93 (m, 2H), 1.75 (m, 2H), 1.55 (m, 2H), 1.25 (m, 1H); ESI MS m/z 
443.05 (M+H)+. 
(S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-piperidine-3’-
carboxylic acid methyl ester (16): White solid; mp 71-72 °C; 1H NMR (300 MHz, CDCl3): δ 
8.29 (d, J = 9.00 Hz, 1H), 7.90 (s, 1H), 7.81 (d, J = 2.70 Hz, 1H), 7.38 (s, 1H), 7.21 (dd, J = 
9.00 Hz, J = 2.40 Hz, 1H), 7.16 (s, 1H), 6.08 (s, 2H), 4.00 (s, 3H), 3.84 (s, 2H), 3.57 (s, 3H), 
3.00 (m, 1H), 2.74 (m, 1H), 2.56 (m, 1H), 2.35 (m, 1H), 2.16 (m, 1H), 1.88 (m, 1H), 1.69 (m, 
1H), 1.54 (m, 2H); ESI MS m/z 408.10 (M+H)+. 
(R)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-piperidine-3’-
carboxylic acid methyl ester (17): White solid; mp 69-71 °C; 1H NMR (300 MHz, CDCl3): δ 
8.29 (d, J = 9.00 Hz, 1H), 7.90 (s, 1H), 7.81 (d, J = 2.40 Hz, 1H), 7.38 (s, 1H), 7.22 (dd, J = 
9.00 Hz, J = 2.40 Hz, 1H), 7.16 (s, 1H), 6.08 (s, 2H), 4.00 (s, 3H), 3.84 (s, 2H), 3.57 (s, 3H), 
3.00 (m, 1H), 2.74 (m, 1H), 2.56 (m, 1H), 2.35 (m, 1H), 2.17 (m, 1H), 1.88 (m, 1H), 1.69 (m, 
1H), 1.54 (m, 2H); ESI MS m/z 408.05 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-aminomethyl-
piperidine hydrochloride (18):  White solid; mp 223-225 °C; 1H NMR (300 MHz, CDCl3): δ 
8.32 (d, J = 9.30 Hz, 1H), 7.92 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.42 (s, 1H), 7.23 (dd, J = 
9.00 Hz, J = 2.70 Hz, 1H), 7.18 (s, 1H), 6.09 (s, 2H), 4.01 (s, 3H), 3.85 (s, 2H), 3.01 (m, 2H), 
2.58 (d, J = 6.0Hz, 2H), 2.04 (m, 2H), 1.70 (m, 2H), 1.30-1.16 (m, 3H); ESI MS m/z 379.10 
(M+H)+. Anal. (C23H26N2O3•2HCl•3H2O) C, N, O, 
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N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-hydroxypiperidine 
(19): White solid; mp 93-95 °C; 1H NMR (300 MHz, CDCl3): δ 8.31 (d, J = 9.00 Hz, 1H), 7.91 
(s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 2.70 Hz, 1H), 7.17 
(s, 1H), 6.09 (s, 2H), 4.01 (s, 3H), 3.85 (s, 2H), 3.72 (m, 1H), 2.84 (m, 2H), 2.23 (m, 2H), 
1.89 (m, 2H), 1.67-1.56 (m, 2H); ESI MS m/z 366.05 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-piperidone (20): 
White solid; 140 °C (decomposed); 1H NMR (300 MHz, CDCl3): δ 8.24 (d, J = 9.00 Hz, 1H), 
7.92 (s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.39 (s, 1H), 7.22 (dd, J = 9.30 Hz, J = 2.70 Hz, 1H), 
7.17 (s, 1H), 6.10 (s, 2H), 4.01 (s, 3H), 3.94 (s, 2H), 3.12 (s, 2H), 2.71 (t, J = 5.40Hz, 2H), 
2.34 (t, J = 7.20 Hz, 2H), 1.20 (t, J = 7.20Hz, 2H); ESI MS m/z 364.10 (M+H)+. 
(S)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-hydroxymethyl-
piperidine (21): White solid; mp 100-102 °C; 1H NMR (300 MHz, CDCl3): δ 8.26 (d, J = 9.30 
Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.70 Hz, 1H), 7.38 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 2.40 
Hz, 1H), 7.16 (s, 1H), 6.08 (s, 2H), 4.00 (s, 3H), 3.82 (s, 2H), 3.62-3.48 (m, 2H), 2.81 (m, 
1H), 2.61 (m, 1H), 2.31 (m, 1H), 2.21 (m, 1H), 1.84-1.71 (m, 2H), 1.66 (m, 1H), 1.60-1.53 (m, 
1H), 1.25 (m, 1H); ESI MS m/z 380.05 (M+H)+. 
(R)-N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-3’-hydroxymethyl-
piperidine (22): White solid; mp 65-67 °C; 1H NMR (300 MHz, CDCl3): δ 8.23 (d, J = 9.00 
Hz, 1H), 7.89 (s, 1H), 7.81 (d, J = 2.70 Hz, 1H), 7.40 (s, 1H), 7.23 (dd, J = 9.00 Hz, J = 2.40 
Hz, 1H), 7.16 (s, 1H), 6.08 (s, 2H), 3.99 (s, 3H), 3.88 (s, 2H), 3.61-3.47 (m, 2H), 2.89 (m, 
1H), 2.67 (m, 1H), 2.33 (m, 1H), 2.24 (m, 1H), 1.82-1.56 (m, 4H), 1.23 (m, 1H); ESI MS m/z 
380.05 (M+H)+. 
N-(2,3-Methylenedioxy-6-methoxyphenanthr-9-ylmethyl)-4’-N-Boc-
aminomethyl-piperidine (23): White solid; mp 211-213 °C; 1H NMR (300 MHz, CDCl3): δ 
8.30 (d, J = 9.30 Hz, 1H), 7.91 (s, 1H), 7.82 (d, J = 2.40 Hz, 1H), 7.40 (s, 1H), 7.23 (dd, J = 
9.00 Hz, J = 2.70 Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.57 (s, 1H), 4.01 (s, 3H), 3.84 (s, 2H), 
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3.02-2.94 (m, 4H), 2.02 (m, 2H), 1.65 (m, 2H), 1.43 (s, 9H), 1.29-1.22 (m, 3H); ESI MS m/z 
479.15 (M+H)+. 
 
3.5.2  Biological assay – In vitro cell growth inhibition assay 
The sulforhodamine B assay was used according to the procedures developed and 
validated at NCI. The in vitro anticancer activities are expressed as IC50 values, which is the 
test compound concentration (μg/mL) that reduced the cell number by 50% after 72 h of 
treatment. The values were interpolated from dose-response data. Each test was performed 
in triplicate with a variation of less than 5%. The IC50 values determined in each of the 
independent tests varied less than 10%. Compound stock solutions were prepared in DMSO 
with the final solvent concentration ≤1% DMSO (v/v), a concentration without effect on cell 
replication. The cells were cultured at 37 °C in RPMI-1640 supplemented with 25 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 2% (w/v) sodium bicarbonate, 
10% (v/v) fetal bovine serum, and 100 μg/mL kanamycin in a humidified atmosphere 
containing 5% CO2. 
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CHAPTER 4 
NEW PHENANTHROINZOLIDINES AND PHENTHROQUINOLIZIDINES  
AS POTENTIAL ANTICANCER AGENTS 
 
4.1 Synthesis of phenanthroindolizidines and phenanthroquinolizidines 
In view of the interesting characteristics of phenanthroindolizidine and 
phenanthroquinolizidine alkaloids as discussed in Chapter 2, the synthesis of these natural 
products has been an appealing area for a long time. Numerous pathways leading to 
racemic compounds have been reported; however, the configuration of these natural 
products has an important effect on their anticancer activity in different cancer cell lines. 
Thus, this section will focus on our new synthetic routes to enantiomerically pure alkaloids 
and their derivatives. Interestingly, the synthetic development of these alkaloids has been 
reviewed in three papers, with each covering progress during a certain period of time.1-3 
Recent progress not included in these papers is described below.  
The first method is the synthesis of S-(+)-tylophorine (Scheme 4-1).4 Compound 24 
was converted to amide 25 through reaction of the acyl chloride with L-(+)-prolinol. The 
hydroxy group then was brominated, and the resulting 26 underwent free radical cyclization 
to give the ring-closed product 27. Finally, the amide carbonyl was reduced to a methylene 
to afford the target tylophorine. However, although several reaction conditions were 
examined, the cyclization step was partially unsuccessful, which has limited further 
application of this synthetic route. 
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Scheme 4-1. Reagents and conditions: (a) i) (COCl)2, DMF; ii) L-(+)-prolinol, Et3N, DMAP, 
97.6% over two steps (b) PBr3, 96% (c) (n-Bu)3SnH, AIBN, 33.6% (d) LiAlH4, AlCl3, 97% 
 
 
Scheme 4-2. Reagents and conditions: (a) LiAlH4, THF, 96% (b) Br2, CHCl3, 92% (c) (S)-N,N-
diethylpiperidine-2-carboxamide, K2CO3, DMF, 93% (d) i) n-BuLi, THF, TMEDA; ii) NaBH4, MeOH, 
90% over two steps (e) Et3SiH, TFA, 94% 
 
The second method is the preparation of 7-methoxy-cryptopleurine (Scheme 4-2). 
Compound 28 was reduced to alcohol 29 and further converted to dibromide 30. Then the 
piperidine moiety was introduced to give 31, and ring closure was accomplished using a 
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Parham-type cycliacylation. The intermediate ketone was reduced with NaBH4 to furnish 32. 
The hydroxy group was removed by reaction of 32 with Et3SiH in TFA. Although 
enantiomerically pure building blocks were used, the final alkaloid was partially racemic, 
possibly due to the instability of 32, as proposed by the authors.5 
 
4.2 New synthetic methodology for antofine and cryptopleurine derivatives 
 
Figure 4-1 Ring and position numbering of phenanthroindolizidines and phenanthroquinolizidines 
 
Most of the known synthetic methodologies were designed to prepare the natural 
alkaloids per se, and as a result, few of these routes are readily derivatizable. Thus, despite 
the numerous syntheses currently available, SAR of this molecular class is largely unknown. 
So far, limited studies have focused only on introducing a hydroxy group at the 
phenanthroindolizidine C14,6 and a few synthetic analogs have been reported with 
variations on the E-ring (Figure 4-1),7,8 This awkward situation makes it quite important to 
develop an efficient, versatile synthetic strategy. With an adaptable route, SAR could be 
better explored and polar functionalities potentially useful for decreasing CNS toxicity could 
be introduced.  
Inspired by the synthetic work reported by Rapoport et al., which is shown in Scheme 
4-3,9 we designed new versatile synthetic methodologies and recently published this work in 
Org. Lett. (Schemes 4-4, 4-5, 4-6, and 4-7).10 In our innovative approach, the E-ring is 
constructed after the D-ring has been conjugated. This synthetic strategy has the following 
merits: the size of the E-ring can be easily altered via ring-closing metathesis and various  
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Scheme 4-3. Synthetic methodology reported by Rapoport etc. 
 
functional groups can be readily introduced during E-ring formation and subsequent 
reactions. The resulting new analogs would provide useful SAR information about the 
alkaloid E-ring. In contrast to Rapoport’s lactam moiety, another novelty in our strategy is the 
use of an oxazolidinone moiety, which not only allows efficient formation of the D-ring, but 
also is easily cleaved to provide the useful synthetic precursor 44.  
As shown in Scheme 4-4, compound 38 was obtained via three steps as reported in 
the literature in 45% yield.11 Subsequent reduction with LiAlH4 was followed by oxidization 
with Py•SO3/DMSO to yield an aldehyde, which was reductively aminated by using D-serine 
methyl ester hydrochloride to give 39 in an overall yield of 59% (three steps). Construction of 
the oxazolidinone ring system was accomplished by reaction of 39 with Im2CO in CH2Cl2 to 
afford 40 in 76% yield. The D-ring was formed by acylation of acid 41 to yield 42 in 79% 
yield. Compound 43 was obtained from 42 by reduction of ketone to methylene in two steps. 
Refluxing 43 with 6N NaOH (aq.) in MeOH successfully cleaved the oxazolidinone to give 
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the key intermediate 44 in 95% yield, from which a series of interesting modifications could 
be achieved. 
 
Scheme 4-4. Synthesis of the key intermediate 44 
 
E7 (50c), with a 7-membered E-ring, was first synthesized from 44, along with the 
two natural products R-antofine (50a) and R-cryptopleurine (50b), with 5- and 6-membered 
E rings, respectively. The amino group of 44 was protected with a Boc group to furnish 45 in 
96% yield (Scheme 4-5). The hydroxy group was then oxidized by Py•SO3 to give an 
aldehyde, which was converted to an alkene 46 by Wittig reagent in 68% yield over two 
steps. After the Boc group was removed, an appropriate unsaturated acid (e.g., 47a: acrylic 
acid; 47b: 3-butenoic acid; 47c: 4-pentenoic acid) was introduced to afford 47 in an average 
yield of 80% using EDC or DEPC (for 47b, double-bond isomerization occurred on the N-
44 
amide side-chain using EDC/HOBt). Cycloalkene analogs (48a-c) were obtained by 
cyclization with Grubb’s 2nd generation (G2) catalyst, and then underwent hydrogenation  
MeO
N
OMe
MeO
H
O
MeO
NH
OMe
MeO
OH
H
44 MeO
NBoc
OMe
MeO
OH
H
45
MeO
NBoc
OMe
MeO
H
46 47a: n = 0; 47b: n = 1
47c: n = 2
n
MeO
N
OMe
MeO
H
n
O
MeO
N
OMe
MeO
H
O
n
48a: n = 0; 48b: n = 1
48c: n = 2
49a: n = 0; 49b: n = 1
49c: n = 2
MeO
N
OMe
MeO
H
n
50a: n = 1; R-antofine
50b: n = 2; R-cryptopleurine
50c: n = 3; E7
(Boc)2O
CH2Cl2,
95%
i) Py-SO3, DMSO
ii) Ph3P=CH2Br,
n-BuLi
68% two steps
i) TFA, CH2Cl2
ii) EDC or DEPC,
HOBt, NMM,DMF
unsaturated acid
76% two steps
Grubb's 2nd
catalyst, CH2Cl2
H2, Pd/C
90%
LiAlH4, THF
70-85%
70-80%
MeO
N
OMe
MeO
H
50d: n = 4; E8  
Scheme 4-5. Synthesis of R-antofine, R-cryptopleurine, E7 and E8 
 
with H2/Pd/C in MeOH to afford 49a-c in high yields. The desired target alkaloids R-antofine 
(50a) and R-cryptopleurine (50b) as well as an E-ring expanded analog (50c) were obtained 
by reduction of amide to amine in an average yield of 70%. The analytical information 
obtained from our synthesized 50a and 50b agreed with the data reported in the 
literature.12,13 By using similar procedures, 8-membered E-ring analog E8 (50d) has been 
synthesized recently (not published).  
The versatility and usefulness of this strategy were further demonstrated by the 
synthesis of S-12-oxo-antofine (54), which contains a ketone in the E-ring (Scheme 4-6). 
Compound 51 was obtained by reacting 46 with 2-methoxyacrylic acid after removal of the 
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Boc group in 83% yield. The ring closure was accomplished using G2 catalyst to give 
compound 52 in 88% yield. Subsequent reduction by LiAlH4 in THF and hydrolysis with HCl 
afforded 54 in 50% yield over two steps to generate a carbonyl functionality at the C12 
position (Scheme 4-6).  
 
Scheme 4-6. Synthesis of S-12-oxo-antofine 
 
Moreover, this novel strategy is also applicable to other natural products in this family, 
such as tylophorine, which has a different substitution pattern on the phenanthrene moiety. 
The key intermediate 44 is the basis of all other modifications reported herein.  
 
4.3  Rationale and Design 
Based on our newly established synthetic strategy, another goal of our research was 
to expand the SAR of these natural alkaloids. Considering that the D-ring opened analogs 
(PBTs) have potent anticancer activity, we next wanted to ascertain how opening the E-ring 
without changing the D-ring would affect. Moreover, as discussed in Chapter 2, Section 2.3, 
analogs with higher polarity might have less CNS toxicity due to potentially reduced BBB 
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penetration. Thus, new derivatives with an additional heteroatom incorporated into the E-ring 
were also investigated (Figure 4-2). This approach is well known to reduce BBB diffusion as 
reported by other studies.14  
 
Figure 4-2 New antofine and cryptopleurine analogs (E-ring opened and heteroatom incorporated) 
 
4.4  Chemistry 
4.4.1  Synthesis of E-ring opened antofine analogs 
 
Scheme 4-7. Reagents and conditions: (a) RCHO, NaBH3CN, MeOH, HOAc, r.t., 60%-90% 
 
The synthesis of E-ring opened analogs is shown in Scheme 4-7. Compound 44 (R 
or S) was reductively aminated with various aldehydes (RCHO) of different sizes and 
NaBH3CN to afford tertiary amines 55-63 in yields from 60% to 90%.  
 
4.4.2  Synthesis of 12-aza-antofines and 12-oxa-antofine  
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Scheme 4-8 Synthesis of 12-aza-antofine analogs 
 
The synthesis of 12-aza-antofine analogs is shown in Scheme 4-8. The primary 
hydroxy group of 45 (R or S) was oxidized to an aldehyde using Py•SO3. The intermediate 
compound was then converted to different secondary amines by way of reductive amination 
using RNH2 and NaBH3CN. Subsequently, the Boc group on the piperidine nitrogen was 
removed by using TFA, and the diamine was reacted with HCHO to give compounds 64-75 
in yields from 40-80% over four steps. Similar methodology was used for the synthesis of 
12-oxa-antofine. However, both isomers (off-white solid, 1H NMR confirmed) decomposed 
quickly even at low temperature (Scheme 4-9). 
 
Scheme 4-9. Reagents and conditions: (a) HCHO, MgSO4, K2CO3, CH2Cl2 
 
4.4.3  Synthesis of 12-aza-cryptopleurines and 12-oxa-cryptopleurine  
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Scheme 4-10. Reagents and conditions: (a) i) Py·SO3, DMSO, Et3N, CH2Cl2; ii) Ph3P+CH2OMeCl-, 
THF, KOtBu, 78% over two steps (b) Hg(OAc)2, THF, H2O, 75% (c) i) RNH2, HOAc, NaBH3CN, MeOH; 
ii) TFA, CH2Cl2; iii) K2CO3, MgSO4, HCHO, CH2Cl2, 40%-70% over three steps 
 
Compound 45 (R or S) was converted to vinylmethyl ether 76 in two steps: oxidation 
of the hydroxyl to an aldehyde followed by Wittig reaction using Ph3P=CH2OMe. To avoid 
deprotection of the Boc group, hydrolysis using Hg(OAc)2 was used to provide aldehyde 77. 
12-Aza-cryptopleurines 78-87 were obtained in 40-70% yields over three steps, reductive 
amination, deprotection of the Boc group, and cyclization using HCHO (Scheme 4-10). 
 
 
Scheme 4-11. Reagents and conditions: (a) i) NaBH4, MeOH; ii) TFA, CH2Cl2; iii) K2CO3, MgSO4, 
HCHO, CH2Cl2, 40% for two steps 
 
The synthesis of 12-oxa-cryptopleurine was also investigated (Scheme 4-11). The 
aldehyde group of 77 (R or S) was reduced to an alcohol with NaBH4, and the resulting 
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intermediate was cyclized to S-13-oxa-cryptopleurine (88) or R-13-oxa-cryptopleurine (89), 
after removal of the Boc group. 
 
4.4.4  Synthesis of 13-aza-cryptopleurines and 13-oxa-cryptopleurine  
The synthesis of 13-aza-crytopleurine analogs is illustrated in Scheme 4-12. 
Compound 45 (R or S) was reacted with Py·SO3 to give an aldehyde, which underwent 
reductive amination with glycine methyl ester hydrochloride in the presence of NaBH3CN to 
give the intermediate 90. The Boc group was in turn removed, and cyclization under basic 
conditions provided an intermediate cyclic amide. In consideration of solubility and easy 
purification, this intermediate was further converted to compound 91, which was reduced to 
the Boc-protected piperizine 92. In the final step, various functionalities were introduced at 
the 13-N either through acylation or reductive amination to give target products 93-109. 
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Scheme 4-12. Reagents and conditions: (a) i) Py·SO3, DMSO, Et3N, CH2Cl2; ii) Glycine methyl ester 
hydrochloride, Et3N, HOAc, NaBH3CN, MeOH, 61% for two steps (b) i) HCl, MeOH; ii) MeOH, Et3N; iii) 
(Boc)2O, Et3N, CH2Cl2, 76% over three steps (c) BMS, THF, 90% (d) i) TFA, CH2Cl2; ii) RCOCl, Et3N, 
CH2Cl2 or RCHO, Et3N, HOAc, NaBH3CN, MeOH, 50-80% for two steps 
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Scheme 4-13. Reagents and conditions: (a) i) ClCH2COCl, Et3N, CH2Cl2, 0 °C;  
ii) NaH, THF, reflux; iii) BMS, THF, 38% for three steps 
 
The synthesis of 13-oxa-cryptopleurine is presented in Scheme 4-13. Compound 44 
(R or S) was reacted with 2-chloroacetyl chloride at 0 °C to give an intermediate amide. 
Then intramolecular nucleophilic attack took place using NaH to give 11-oxo-13-oxa-
cryptopleurine. In the final step, the amide was reduced by BMS to give compound 110 or 
111.  
 
4.4.5  Synthesis of 13-oxa-E7  
 
Scheme 4-14. Reagents and conditions: (a) i) NaBH4, MeOH; ii) TFA, CH2Cl2; iii) ClCH2COCl, Et3N, 
CH2Cl2, 0 °C; iv) NaH, THF, reflux; v) BMS, THF, 24% for five steps  
 
The synthesis of 7-membered E-ring analogs is shown in Scheme 4-14. The 
aldehyde of 77 was reduced to a primary alcohol and the Boc group was then removed with 
TFA. The same three reaction steps used in the preparation of 110 above were used to give 
112 in 24% yield over five steps.  
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4.5  Results and discussion 
4.5.1 Anticancer activity of compound 54, E7, and E8 
The new compounds E7 (7-membered E-ring) and E8 (8-membered E-ring) were 
screened in vitro against a panel of human tumor cell lines, including A549 (lung), KB 
(nasopharyngeal), DU-145 (prostate), and HCT-8 (colon), using R-antofine and R-
cryptopleurine as a comparison. The results (IC50) are listed in Table 4-1. Interestingly, 
compound E7 showed significant cytotoxic activity. Compared with R-antofine, E7 was 
equipotent against A549 cell growth; it also had improved selectivity as it exhibited reduced 
potency against KB and DU145 tumor cell lines. E7 was also much more selective, although 
less potent, than R-cryptopleurine against both A549 and HCT-cell lines. These results 
suggest that the E-ring size may affect the interaction between the molecule and the binding 
site in the target, and the expansion of the E-ring may play a role in the anticancer selectivity.  
Although moderate to significant reduction in cytotoxicity was observed for compound 54, 
further modifications on the ketone are of great interest to potentially improve the anticancer 
activity. Unfortunately, analog E8 with further expanded E-ring exhibited significant loss of 
anticancer activity, suggesting the possible incompatibility of the 8-membered E-ring with its 
putative target(s).  
Compound A549 (nM) DU145 (nM) KB (nM) HCT-8 (nM) 
R-antofine 22 25 36 ND 
R-cryptopleurine 1.38 1.59 1.51 1.09 
E7 25 179 102 10 
54 290 710 480 420 
E8 1410 2080 1800 2760 
Table 4-1 GI50 values of R-antofine, R-cryptopleurine, 54, E7 and E8 
 
4.5.2  Anticancer activity of E-ring opened analogs 
Compounds 55-63 were tested against a panel of four cancer cell lines and the IC50 
values are listed in Table 4-2.  
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Compound R Configuration IC50 (μM) A549 DU145 KB HCT-8 
55 -Et R 0.99 1.44 1.07 1.31 
56 -nPr R 1.31 1.01 0.51 1.62 
57 -cPentyl R 1.24 1.40 0.95 1.66 
58 -CH2cPentyl R 1.45 1.45 1.26 1.95 
59 -iBu R 2.37 1.93 1.56 2.15 
60 -cBu R 1.67 1.60 1.67 2.16 
61 -CH2cPr R 2.18 1.91 2.18 2.48 
62 -nPr S 1.97 1.79 1.74 2.28 
63 -CH2cPr S 2.16 1.96 1.77 2.31 
Antofine - R 0.022 0.025 0.036 - 
Table 4-2 IC50’s of E-ring opened analogs 
The opening of the E-ring resulted in substantially decreased (ca. 50-fold) anticancer 
activity compared with antofine. In this series, all compounds displayed similar activity with 
IC50 values around 1-2 μM. Thus, although several alkyl groups with different sizes and 
chain lengths were introduced, a definite SAR could not be generalized at this point. 
Meanwhile, the effect of the chiral center was negligible as seen from comparison of 56 with 
62 and 61 with 63. These data suggested that an intact E-ring is crucial for the potency of 
this alkaloid type. 
 
4.5.3  Anticancer activity of 12-aza-antofines 
 
Compound R Configuration IC50 (μM) A549 DU145 KB HCT-8 
64 -CH2Ph S 5.30 4.95 5.70 3.63 
65 -iBu S 2.00 6.60 4.40 1.82 
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66 -nPr S 3.94 7.38 6.64 2.71 
67 -(CH2)2Ph S 6.62 10.20 10.03 7.47 
68 -(CH2)2OH S 4.41 6.36 7.83 10.77 
69 -Ph S > 40 > 40 36.32 20.20 
70 -cPr S 1.80 3.70 2.71 1.85 
71 -Me S 0.66 2.03 1.72 1.00 
72 -NMe2 S 1.67 2.26 2.31 2.01 
73 -CH2Ph R 2.68 4.62 3.41 1.87 (KBvin)
74 -NMe2 R 4.15 6.01 2.38 10.98 (KBvin)
75 -Me R 0.66 1.00 0.79 0.66 
Antofine - R 0.022 0.025 0.036 - 
Table 4-3 IC50’s of 12-aza-antofine analogs 
 
As shown in Table 4-3, 12-aza-antofine analogs had significantly reduced anticancer 
activity compared with antofine. With the exception of 71 and 75, most analogs had an 
average IC50 greater than 1 μM. In general, compounds with a larger amino substituent (64, 
67, and 69) were less active than those with smaller N substitutions (71, 72, and 75). The 
influence of the chiral center was not conclusive as 72 (S isomer) was two-fold more active 
than 74 (R isomer), while 71 (S isomer) was slightly less potent than 75 (R isomer). Analog 
75 was the most potent in this series with IC50 values of 0.66–1.00 μM. Except for 75, the 
12-aza analogs were generally less potent than the E-ring opened analogs. The conclusion 
drawn from these data is that introducing nitrogen at the C12 position of antofine results in 
decrease or loss of activity, even though the polarity of the molecules might be increased.  
Conformational analysis (MM2 force field minimization, Chemdraw 11.0) indicated that 71 
had a flatter confirmation than R-antofine, while 75 had a more folded one (Figure 4-3). It is 
also possible that the E-ring might be metabolically unstable due to the presence of the 
aminal (aminoacetal) structure. In addition, introducing the side chain at C12 might disfavor 
binding in the potential binding pocket. Further studies are still needed to investigate these 
possibilities. 
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71 75
R-antofine
 
Figure 4-3 Conformational analysis of compound 71, 75, and R-antofine  
(Gray: C; White: H; Red: O; Blue: N; Conformations obtained with MM2 force field minimization) 
 
4.5.4  Anticancer activity of 12-aza (or oxa)-cryptopleurine analogs and SAR 
discussion 
 
Compound R Configuration IC50 (μM) A549 DU145 KB HCT-8 
78 -(CH2)2OH S 5.68 1.99 1.59 10.65 
79 -Ph S > 40 > 40 > 40 28.38 
80 -iBu S 1.52 2.30 5.06 1.36 
81 -CH2Ph S 29.88 > 40 > 40 21.34 
82 -CH2cPr S 4.30 14.33 11.47 5.73 
83 -NMe2 S 1.78 2.97 3.08 2.37 
84 -iBu R 5.11 1.66 1.45 7.32 (KBvin)
85 -NMe2 R 5.20 3.00 2.84 5.30 (KBvin)
86 -(CH2)2OH R 2.48 1.46 2.22 > 20 (KBvin)
87 -CH2cPr R 1.12 1.20 2.10 5.68 (KBvin)
Cryptopleurine - R 1.38 nM 
1.59 
nM 
1.51 
nM 1.09 nM 
Table 4-4 IC50’s of 12-aza-cryptopleurine analogs 
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The synthesis of 12-aza-cryptopleurine analogs failed to generate any promising 
results. As shown in Table 4-4, significant decreases in potency were observed relative to 
cryptopleurine. Similar to the 12-aza-antofine analogs, a larger side chain (compounds 79 
and 81) led to greater reduction in activity. The effect of R or S configuration on efficacy was 
found to be minimal, as 80 and 84 exhibited comparable levels of cell growth inhibition. Both 
80 and 84 were more folded than R-cryptopleurine (Figure 4-4). Thus, the activity loss might 
be explained by conformational mismatch, or possible instability of the aminal structure in 
cells, or incompatibility of the C-12 side chain with the binding pocket. All of these possible 
explanations remain to be investigated in further studies.   
However, the 12-oxa-cryptopleurine analogs 88 and 89 showed greater anticancer 
activity, in the low μM level, compared with the 12-aza analogs.  Both 88 and 89 were 
equipotent against the four tested cell lines (Table 4-5). Accordingly, the molecular entity 
 
Figure 4-4 Conformational analysis of compound 80, 84, and R-cryptopleurine  
(Gray: C; White: H; Red: O; Blue: N; Conformations obtained with MM2 force field minimization) 
exerting anticancer activity in the cells might actually be the E-ring opened analogs (due to 
instability of the cyclic hemiaminal ether), which could indirectly explain the similar observed 
cytotoxicity between these 12-oxa analogs and the compounds in Section 4.5.1.  
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Compound Configuration IC50 (μM) A549 DU145 KB HCT-8 
88 S 1.79 1.82 1.66 1.45 
89 R 1.37 1.29 1.10 1.26 
Cryptopleurine R 1.38 nM 1.59 nM 1.51 nM 1.09 nM 
Table 4-5 IC50’s of 12-oxa-cryptopleurine analogs 
 
4.5.5  Anticancer activity of 13-aza (or oxa)-cryptopleurine analogs and SAR 
discussion 
The synthesized 13-aza-crytopleurine analogs were tested against five cancer cell 
lines (Table 4-6). Different side-chain functionalities were introduced for a comprehensive 
SAR investigation. Unfortunately, all compounds showed substantially decreased 
cytotoxicity compared with R-cryptopleurine. However, among the 15 aza-analogs, 99 
obviously displayed the highest potency, with the HCT-8 and A549 cell lines being 
 
Compound R Configuration IC50 (μM) A549 DU145 KB HCT-8 
93 H (HCl salt) S 1.73 2.08 1.79 1.62 
94 -Et S 7.13 10.48 8.24 9.45 
95 -CO2Me S 10.93 12.19 11.32 12.05 
96 -COCH3 S 11.65 11.94 15.46 13.82 
97 -SO2Me S 14.52 16.79 17.52 17.83 
98 -CH2CO2Me S 14.74 20.82 14.65 14.03 
99 -CH2cPr S 0.79 2.94 6.57 0.25 
100 -cPr S 23.18 17.92 23.42 13.02 
101 -COPh S 15.00 15.71 20.10 18.11 
102 -(CH2)2OH S 14.08 12.62 8.62 7.41 
103 -PO3Me2 S 12.18 18.25 8.09 
10.42 
(KBvin)
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104 -Me S 9.73 7.13 5.30 6.45 
105 -CH2Ph S > 20 > 20 16.85 
15.24 
(KBvin)
106 -CONMe2 R 14.08 13.12 12.32 
11.41 
(KBvin)
107 -iBu R 12.86 12.24 11.25 9.96 (KBvin)
108 -CH2Ph R 16.43 11.87 12.14 
7.64 
(KBvin)
109 -CH2cPr R > 20 > 20 > 20 
13.44 
(KBvin)
Cryptopleurine - R 1.38 nM 1.59 nM 1.51 nM 1.09 nM
Table 4-6 IC50’s of 13-aza-cryptopleurine analogs 
 
particularly sensitive (IC50 = 0.25 and 0.79 µM, respectively). Compound 93 was less potent 
than 99, but exhibited similar potency against all four tested cell lines with IC50 values 
ranging from 1.62 to 2.08 µM. The effect of chirality was not obvious from these data since 
for 99 and 109, the S isomer was much more active, whereas for 105 and 108, the R isomer 
was a little more potent. In order to explain the loss of activity relative to R-cryptopleurine, a 
conformational comparison was performed for compounds 93 and 99 (Figure 4-5).   
 
Figure 4-5 Conformational analysis of compound 93 and 99 (Gray: C; White: H; Red: O; Blue: N; 
Conformations obtained with MM2 force field minimization) 
 
In contrast to the planar characteristics of cryptopleurine (see Figure 4-4), the 
conformation of 93 was tilted at the C13 position due to the presence of the N atom. A tilt in 
the reverse direction was introduced into 99 by the incorporation of the cyclopropylmethyl 
group. One possible explanation for the activity loss is that compounds 93 and 99 have 
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different pKa’s from cryptopleurine due to the N- incorporation, which is likely to affect their 
anticancer activity due to changes in pharmacodynamic properties.15 In view of these data, it 
can be concluded that introducing a nitrogen atom at the C13 position of cryptopleurine is 
detrimental to the anticancer activity. Despite such disappointing results, continuing 
synthetic efforts produced both R- and S-13-oxa-cryptopleurine analogs (Table 4-7). 
 
Compound Configuration IC50 (μM) A549 DU145 KB HCT-8 
110 S 23 nM 62 nM 37 nM 9 nM 
111 R 13.95 7.05 6.68 3.45 
Cryptopleurine R 1.38 nM 1.59 nM 1.51 nM 1.09 nM 
Table 4-7 IC50’s of 13-oxa-cryptopleurine analogs 
 
Surprisingly, compound 110 exhibited profound cytotoxicity, though less than those 
of R-cryptopleurine, while its enantiomer 111 showed merely modest inhibition at the low μM 
level. Improved selectivity was observed for 110 against HCT-8 cancer cell lines, relative to 
R-cryptopleurine, which was equipotent against all four cell lines. Conformational analysis 
suggested that 110 resembled R-cryptopleurine in terms of calculated conformation (Figure 
4-6). It is striking that although compound 110 (13-oxa-cryptopleurine) had almost the same 
conformation as compound 93 (13-aza-cryptopleurine), 110 was much more potent. The 
difference in their basicity due to the introduction of the additional N atom might explain the 
disparity.  
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Figure 4-6 Conformational analysis of compound 110 (Gray: C; White: H; Red: O; Blue: N; 
Conformations obtained with MM2 force field minimization) 
 
4.5.6 Anticancer activity of 13-oxa-E7  
The GI50 values of compound 112 are presented in Table 4-8.  
Compound Configuration A549 (nM) DU145 (nM) KB (nM) HCT-8 (nM)
112 S 41 119 68 20 
E7 R 25 179 102 10 
Table 4-8 IC50’s of 13-oxa-E7 
 
Compound 112, with an additional oxygen atom introduced at the 13-position, and 
E7 showed the same rank order of potency (HCT-8 > A549 > KB > DU145). Against A549 
and HCT-8cancer cell lines, 112 exhibited slightly reduced activity (41 nM and 20 nM, 
respectively) compared with E7, while for DU145 and KB, 112 was more potent than E7. 
The strong potency against the HCT-8 cell line indicated that these compounds might be 
developed as potential anti-colon cancer agents based on our preliminary in vitro data. 
 
Figure 4-7 Conformational analysis of compound E7 and 112 (Gray: C; White: H; Red: O; Blue: N; 
Conformations obtained with MM2 force field minimization) 
 
Conformational analysis indicated that E7 was more twisted upward than 112 and R-
cryptopleurine in terms of the D- and E-ring, which might be the source of the improved 
specificity against different cancer cell lines (see also Section 4.5.1). In addition, when the 
60 
dihedral angle between the D- and E-ring was decreased as in 112, the selectivity was 
somehow weakened, as with R-cryptopleurine that also possesses a flat conformation.  
 
4.6  Conclusions 
In summary, through our synthetic efforts, the following conclusions can be made: 
1. E-ring opening is detrimental to cytotoxicity 
2. Incorporation of a N heteroatom and corresponding N-substitutions at the C12 
position of antofine and cryptopleurine results in loss of activity 
3. Incorporation of a N atom and corresponding N-substitutions at the C13 position of 
cryptopleurine reduces the inhibition of cancer cell growth 
4. Incorporation of an O atom at the 13-position of R-cryptopleurine maintains the 
impressive anticancer activity and improves selectivity among different cancer cell 
lines 
5. Incorporation of an O atom at the 13-position of E7 retains the high potency and 
enhanced selectivity 
 
Finally, regarding the CNS toxicity, a blood-brain barrier (BBB) penetration prediction 
was performed for selected natural alkaloids and new synthetic analogs. The values are 
shown in Table 4-9. As discussed in Chapter 2, compounds with higher polarity and, 
accordingly, possibly lower BBB penetration might not have deleterious CNS side effects. 
The predicted BBB penetration values for tylophorine (0.076) and tylocrebrine (1.527) are 
consistent with their animal results and clinical behavior, i.e., tylocrebrine with a higher ratio 
failed phase I clinical trial, while tylophorine with a lower ratio exhibited no toxicity up to 500 
mg/kg in rats. Antofine (0.980) has a higher predicted ratio than cryptopleurine (0.281), 
indicating a potentially higher distribution in the brain. However, CNS side effects are a 
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common phenomenon within this class of molecules, even for cryptopleurine, which has 
been confirmed generally toxic in NCI studies even with a relatively low predicted ratio.  
 
Compound Structure Predicted BBB penetration  (C.brain/C.blood) 
Tylophorine 0.076 
Tylocrebrine 1.527 
Antofine 0.980 
Cryptopleurine 0.281 
56 0.230 
75 0.060 
83 0.079 
89 0.034 
93 0.080 (free amine) 
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99 0.189 
110 0.071 
112 0.059 
Table 4-9 Prediction of BBB penetration for selected analogs and natural products 
 
In Table 4-9, the new synthetic analogs generally had lower predicted BBB values, 
indicating that they might have reduced CNS toxicity compared with the natural alkaloids, 
Incorporation of heteroatoms might lead to more favorable polarity. Among these new 
derivatives, compound 110 is quite interesting, not only because it displayed potent 
anticancer activity at a low nM level, but also has a much lower predicted BBB ratio than 
cryptopleurine, indicative of possibly improved pharmacokinetic and pharmacodynamic 
profiles. The calculated value for compound 112 is even lower than that of 110, and as it has 
selectivity has been confirmed against the HCT-8 cancer cell line with an IC50 of 20 nM, this 
compound might have potential application in the treatment of colon related cancers. 
 
4.7  Experimental section 
4.7.1  Chemistry 
Materials and Methods. Melting points were measured with a Fisher Johns melting 
apparatus without correction. 1H NMR spectra were measured on a 300 MHz Varian Gemini 
2000 spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Mass spectra were measured on a Shimadzu LC-MS2010 instrument. Thin-layer 
chromatography (TLC) and preparative TLC were performed on precoated silica gel GF 
plates purchased from Merck, Inc. Biotage Flash+ or Isco Companion systems were used 
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for flash chromatography. Silica gel (200-400 mesh) from Aldrich, Inc. was used for column 
chromatography. All other chemicals were obtained from Aldrich, Inc., and Fisher, Inc.  
N-(2,3,6-Trimethoxyphenanthren-9-ylmethyl)-D-serine methyl ester (39): 
Compound 38 (15.56 g, 47.73 mmol) was suspended in 400 mL of THF, to which LiAlH4 
(2.729 g, 71.60 mmol) was added carefully at rt. After 2 h, water and 1N NaOH were added 
to quench the reaction, which was then filtered. Removal of the solvent in vacuo gave a 
white solid, which was then dissolved in CHCl3, washed with water and brine, and dried over 
MgSO4. After removing solvent, the crude product was used in the next step without further 
purification.  
The white solid was suspended in Et3N (18 mL) and CH2Cl2 (400 mL) at 0 °C, and 
then Py•SO3 (22.90 g, 143.19 mmol) in 80 mL of DMSO was added dropwise. The reaction 
was monitored by TLC before 150 mL of HCl (1N) was added. The organic layer was then 
washed with sat. NaHCO3, brine, and dried over MgSO4.  
After evaporation of the solvent, the resulting yellow oil was dissolved in CH2Cl2 (100 
mL) and MeOH (300 mL) at 0 °C, to which D-serine hydrochloride (6.22 g, 40 mmol) and 
Et3N (5.70 mL, 41 mmol) were added. The reaction was stirred at 0 °C for 30 min before 
HOAc (4.42 mL, 77.60 mmol) and NaBH3CN (5.133 g, 77.60 mmol) were added.  The 
reaction mixture was then warmed to rt and stirred overnight. Sat. NaHCO3 was added to 
quench the reaction, and the mixture extracted with CH2Cl2. The organic layers were 
collected, washed with brine, dried over Na2SO4. Column chromatography eluting with 
CH2Cl2/MeOH gave 39 (11.38 g, 59.7% for three steps) as a light yellow solid: mp 97-99 °C; 
[α]23D= 15.1 ° (c 2.56, CHCl3); 1H NMR (300 MHz, CDCl3): δ 8.12 (d, J = 9.0 Hz, 1H), 7.88 (d, 
J = 2.4 Hz, 1H), 7.84 (s, 1H), 7.47 (s, 1H), 7.24 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.18 (s, 1H), 
4.33 (d, J = 12.9 Hz, 1H), 4.13 (d, J = 13.2 Hz, 1H), 4.09 (s, 3H), 4.02 (s, 3H), 4.01 (s, 3H), 
3.78 (m, 1H), 3.75 (s, 3H); 3.58 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 173.7, 158.2, 149.8, 
149.3, 131.9, 131.5, 127.3, 126.2, 124.9, 124.4 (2×C), 115.4, 108.5, 104.9, 103.6, 62.8, 62.4, 
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56.3, 56.1, 55.7, 52.4, 50.8; ESI-HRMS ([M + H]+) calcd for C22H26NO6 400.1760, found 
400.1764. 
(R)-Methyl-N-(2,3,6-trimethoxyphenanthren-9-ylmethyl)-oxazolidinone-4-
carboxylate (40): The ester 39 (6.30 g, 15.77 mmol) was dissolved in 200 mL of CH2Cl2 at 
room temperature, to which 1,1'-carbonyldiimidazole (5.11 g, 31.54 mmol) was added. The 
mixture was stirred at reflux overnight. Column chromatography eluting with CH2Cl2/MeOH 
gave 40 (5.10 g, 76%) as a light yellow solid: mp 83-85 °C; [α]23D= 11.5 ° (c 1.36, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.99 (d, J = 9.0 Hz, 1H), 7.83 (d, J = 2.4 Hz, 1H), 7.78 (s, 1H), 
7.33 (s, 1H), 7.21 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.13 (s, 1H), 5.28 (d, J = 14.7 Hz, 1H), 
4.61 (d, J = 14.7 Hz, 1H), 4.28-4.27 (m, 2H), 4.07 (s, 3H), 4.01 (s, 3H), 3.98 (s, 3H), 3.95 (dd, 
J = 8.7 Hz, J = 5.4 Hz, 1H), 3.64 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 170.4, 158.5, 157.4, 
149.9, 149.8, 132.0, 127.2, 126.8, 126.3, 126.2, 124.9, 124.3, 115.7, 108.5, 105.2, 103.6, 
64.8, 56.3, 56.1 (2×C), 55.7, 52.9, 46.3; ESI-HRMS ([M + H]+) calcd for C23H24NO7 426.1553, 
found 426.1566. 
(R)-N-(2,3,6-Trimethoxyphenanthren-9-ylmethyl)-oxazolidinone-4-carboxylic 
acid (41): The oxazolidinone (5.10 g, 12.00 mmol) was dissolved in 1,4-dioxane (100 mL), 
to which aq. KOH (2N, 50 mL) was added. The mixture was stirred at rt for 1.5 h, and then 
cooled to 0 °C. The pH was adjusted to 3 with 85% H3PO4. The resulting solid was collected 
and washed sequentially with cold water, cold MeOH, and diethyl ether.  After being dried 
under vacuum, 4.10 g of white solid were obtained. Yield: 83%; mp 248-250 °C; [α]23D= -
4.8 ° (c 0.23, MeOH); 1H NMR (300 MHz, DMSO-d6): δ 8.14 (d, J = 2.4 Hz, 1H), 8.07 (s, 1H), 
7.97 (d, J = 9.3 Hz, 1H), 7.49 (s, 1H), 7.43 (s, 1H), 7.27 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 
5.19 (d, J = 15.3 Hz, 1H), 4.52 (d, J = 15.6 Hz, 1H), 4.44 (t, J = 9.3 Hz, 1H), 4.31 (dd, J = 9.0 
Hz, J = 3.3 Hz, 1H), 4.04 (m, 1H), 4.03 (s, 3H), 4.00 (s, 3H), 3.92 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6): δ 171.3, 157.9, 157.2, 149.5, 149.3, 131.6, 127.1, 126.4, 125.3, 124.5, 124.1, 
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123.6, 115.8, 108.7, 105.1, 104.2, 64.8, 55.9, 55.8, 55.5 (2×C), 45.0; ESI-HRMS ([M - H]-) 
calcd for C22H20NO7 410.1240, found 410.1255. 
(R)-11,14-Dioxo-12-oxa-antofine (42): The acid (5.06 g, 12.31 mmol) was 
suspended in CH2Cl2 (200 mL) and DMF (1 mL), to which (COCl)2 (3.75 mL, 43.09 mmol) 
was added. The mixture was stirred for 1 h, and then SnCl4 (5.76 mL, 49.24 mmol) was 
added dropwise. The mixture was then warmed to 50°C and stirred overnight. The reaction 
was quenched with HCl (2N). After normal workup, column chromatography eluting with 
CH2Cl2/MeOH gave 42 (4.60 g, 95%) as a light yellow solid: mp 244 °C (dec.); [α]23D= -
204.4 ° (c 0.59, CHCl3); 1H NMR (300 MHz, CDCl3): δ 9.07 (s, 1H), 7.95 (d, J = 9.3 Hz, 1H), 
7.81 (d, J = 2.7 Hz, 1H), 7.79 (s, 1H), 7.26 (dd, J = 9.3 Hz, J = 2.7 Hz, 1H), 5.59 (d, J = 18.0 
Hz, 1H), 4.93 (dd, J = 13.2 Hz, J = 9.0 Hz, 1H), 4.92 (d, J = 17.7 Hz, 1H), 4.68 (t, J = 9.0 Hz, 
1H), 4.51 (ddd, J = 9.0 Hz, J = 4.2 Hz, J = 1.5 Hz, 1H), 4.11 (s, 3H), 4.09 (s, 3H), 4.06 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ 193.5, 161.4, 157.4, 150.8, 149.4, 139.0, 134.8, 127.0 
(2×C), 124.7, 124.3, 121.3, 116.6, 108.1, 104.9, 103.3, 64.9, 58.3, 56.1, 56.0, 55.8, 42.3; 
ESI-HRMS ([M + H]+) calcd for C22H20NO6 394.1291, found 394.1296.                                                             
(S)-11-Oxo-12-oxa-antofine (43): The ketone (4.60 g, 11.70 mmol) was suspended 
in MeOH, to which NaBH4 (888 mg, 23.40 mmol) was added at r.t. The mixture was stirred 
for 1 h before sat. NaHCO3 was added. Most solvent was removed by evaporation and the 
solid was collected by filtration, washed with cold MeOH and diethyl ether. The white solid 
was then dissolved in TFA (200 mL) and Et3SiH (3.75 mL, 23.40 mmol) and refluxed for 1 h. 
TFA was removed under reduced pressure. Column chromatography eluting with 
CH2Cl2/MeOH furnished 43 (4.21 g, 95%) as a white solid: mp 253-255 °C; [α]23D= -177.5 ° 
(c 0.44, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 3.0 Hz, 1H), 7.78 (d, 
J = 9.0 Hz, 1H), 7.24 (dd, J = 9.6 Hz, J = 3.0 Hz, 1H), 7.22 (s, 1H), 5.18 (d, J = 16.5 Hz, 1H), 
4.73 (t, J = 8.1 Hz, 1H), 4.71 (d, J = 16.5 Hz, 1H), 4.34 (dd, J = 8.7 Hz, J = 5.1 Hz, 1H), 
4.17-4.09 (m, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.03 (s, 3H), 3.41 (dd, J = 15.9 Hz, J = 4.2 Hz, 
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1H), 2.97 (dd, J = 15.6 Hz, J = 10.8 Hz, 1H); 13C NMR (75 MHz, CDCl3 and CD3OD): δ 
158.3, 157.7, 149.8, 149.0, 130.6, 126.2, 124.2, 124.1, 123.6, 123.1, 122.6, 115.5, 105.0, 
104.2, 103.9, 69.2, 56.2, 56.1, 55.7, 50.9, 41.8, 30.8; ESI-HRMS ([M + H]+) calcd for 
C22H22NO5 380.1498, found 380.1478. 
(S)-(6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-yl)methanol 
(44): 11-Oxo-12-oxa-antofine (4.21 g, 11.10 mmol) was suspended in 100 mL of MeOH and 
50 mL of NaOH (6N), and the mixture was stirred at 100 °C overnight. Most solvent was 
removed by evaporation and the residue was suspended in 200 mL of cold water. The solid 
was filtered, washed sequentially with cold MeOH and diethyl ether, and dried under 
vacuum to give 3.61 g of white solid. Yield: 92%; mp 243-245 °C; [α]23D= 100 ° (c 0.71, 
CHCl3); 1H NMR (300 MHz, DMSO-d6): δ 8.08 (s, 1H), 8.07 (d, J = 2.7 Hz, 1H), 7.80 (d, J = 
9.0 Hz, 1H), 7.31 (s, 1H), 7.21 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.79 (t, 8.5 Hz, 1H), 4.42 (d, 
J = 16.2 Hz, 1H), 4.18 (d, J = 16.2 Hz, 1H), 4.02 (s, 3H), 3.98 (s, 3H), 3.94 (s, 3H), 3.68-3.63 
(m, 1H), 3.56-3.51 (m, 1H), 3.01-2.97 (m, 2H), 2.67-2.58 (m, 1H); 13C NMR (75 MHz, 
DMSO-d6): δ 157.6, 149.6, 148.6, 129.9, 127.8, 127.0, 125.5, 124.4, 123.8, 123.2, 115.7, 
105.0 (2×C), 104.2, 65.7, 56.2, 55.8, 55.7, 55.2, 46.1, 29.2; ESI-HRMS ([M + H]+) calcd for 
C21H24NO4 354.1705, found 354.1702. 
(S)-N-Boc-(6,7,10-trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-
yl)methanol (45): (Boc)2O (3.14 g, 14.40 mmol) was added to the amino-alcohol (4.240 g, 
12 mmol) in 100 mL of CH2Cl2 and Et3N (6 mL), and the mixture was stirred for 2 h. HCl (50 
mL, 1N) was added and the organic layer was separated, washed with sat. NaHCO3 and 
brine, and dried over MgSO4. Column chromatography eluting with CH2Cl2/MeOH gave 5.20 
g of compound 45 as a white solid. Yield: 95.6%; mp 105-107 °C; [α]23D= 85.5 ° (c 0.42, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.89 (s, 2H), 7.81 (d, J = 9.0 Hz, 1H), 7.28 (s, 1H), 
7.22 (d, J = 8.7 Hz, 1H), 5.29 (br s, 1H), 4.84 (m, 1H), 4.61 (br s, 1H), 4.09 (s, 3H), 4.05 (s, 
3H), 4.01 (s, 3H), 3.73-3.62 (m, 2H), 3.27 (dd, J = 16.5 Hz, J = 6.3 Hz, 1H), 3.18 (t, J = 16.5 
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Hz, 1H), 1.55 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 157.9, 156.2, 149.7, 148.8, 130.4, 126.7, 
124.0, 123.9, 123.8, 123.4, 122.8, 115.2, 105.1, 104.2, 104.0, 80.6, 62.7, 56.2, 56.0, 55.7, 
50.6, 41.0, 28.6 (3×C), 26.5; ESI-HRMS ([M + H]+) calcd for C26H32NO6 454.2230, found 
454.2246. 
(S)-tert-Butyl-6,7,10-trimethoxy-3-vinyl-3,4-dihydrodibenzo[f,h]isoquinoline-
2(1H)-carboxylate (46): To a solution of Ph3P=CH2Br (1.43 g, 4 mmol) in THF was added n-
BuLi (2M in heptanes, 1.95 mL) at 0 °C under N2. The mixture was stirred for 0.5 h before 
compound 45 (906 mg, 2 mmol) in THF (20 mL) was added dropwise. The mixture was then 
stirred for 2 h (monitored by TLC). Sat. NH4Cl was added to quench the reaction and THF 
was removed by evaporation. The residue was dissolved in CH2Cl2 (50 mL), washed with sat. 
NaHCO3 and brine, and dried over MgSO4. Column chromatography eluting with 
EtOAc/Hexane gave 46 (684 mg, 76%) as a light yellow foam: mp 177-179 °C; [α]23D= 
118.2 ° (c 0.56, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 
7.85 (d, J = 9.0 Hz, 1H), 7.31 (s, 1H), 7.23 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 5.86-5.75 (m, 
1H), 5.29 (m, 1H), 5.26 (d, J = 16.8 Hz, 1H), 5.16-5.04 (m, 2H), 4.59 (d, J = 17.4 Hz, 1H), 
4.11 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.36 (dd, J = 16.2 Hz, J = 6.0 Hz, 1H), 3.29 (t, J = 
16.5 Hz, 1H), 1.55 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 157.9, 155.3, 149.8, 148.8, 136.5, 
130.4, 126.8, 124.4, 124.2, 123.9, 123.6, 123.1, 116.6, 115.2, 105.1, 104.3, 104.1, 80.3, 
77.4, 56.3, 56.1, 55.7, 41.1, 29.8, 28.7 (3×C); ESI-HRMS ([M + Na]+) calcd for C27H31NO5Na 
472.2100, found 472.2103. 
General procedures for the synthesis of 47a-c: Compound 46 (225 mg, 0.50 
mmol) was dissolved in TFA/CH2Cl2 (10 mL) at rt, and the mixture was stirred for 1 h. The 
solvent was removed by evaporation and TFA was neutralized with NMM. The residue was 
redissolved in DMF (10 mL), to which the appropriate unsaturated acid (0.70 mmol), EDC 
hydrochloride (134 mg, 0.70 mmol), HOBt (95 mg, 0.70 mmol), NMM (0.35 mL) were added.  
Stirring was continued overnight. DMF was then removed under reduced pressure, and the 
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residue was dissolved in CH2Cl2 (30 mL), washed with HCl (1N), sat. NaHCO3, and brine, 
and dried over MgSO4. Compounds 47a and 47c were isolated by column chromatography 
eluting with MeOH/CH2Cl2. For 47b, the unsaturated acid (1.50 mmol) was added to a 
mixture of amine (0.50 mmol), DEPC (0.25 mL, 1.50 mmol), and Et3N (0.42 mL, 3.00 mmol) 
in DMF, which was stirred overnight at room temperature. Standard workup and 
chromatography with EtOAc/Hexane gave 47b in 76% yield. 
47a: mp 104-106 °C; [α]23D= 136 ° (c 0.58, CHCl3); 1H NMR (300 MHz, CDCl3, 
compound rotameric at rt): δ 7.86 (m, 3H), 7.26 (s, 1H), 7.21 (dd, J = 9.3 Hz, J = 2.4 Hz, 1H), 
6.77 (brs, 1H), 6.40 (d, J = 16.8 Hz, 1H), 5.93-5.57 (m, 3H), 5.24-5.01 (m, 3H), 4.83-4.59 (d, 
J = 17.1 Hz, 1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.02 (s, 3H), 3.33 (s, 2H); 13C NMR (75 MHz, 
CDCl3): δ 166.7, 166.1, 157.9, 149.6, 148.7, 136.0, 130.4, 128.3, 126.3, 123.8, 123.2, 122.0, 
117.4, 115.1, 105.1, 104.9, 104.1, 103.8, 57.0, 56.2, 56.0, 55.9, 55.7, 55.5, 52.9, 48.1, 42.7, 
40.1, 30.6, 29.8, 28.9; ESI-HRMS ([M + H]+) calcd for C25H26NO4 404.1862, found 404.1854. 
47b: mp 170-172 °C; [α]23D= 125.1 ° (c 0.64, CHCl3); 1H NMR (300 MHz, CDCl3, 
compound rotameric at rt): δ 7.95-7.73 (m, 3H), 7.32-7.23 (m, 2H), 6.09-6.03 (m, 1H), 5.89-
5.77 (m, 3H), 5.27-5.01 (m, 4H), 4.85-4.53 (d, J = 17.4 Hz, 1H), 4.11 (s, 3H), 4.07 (s, 3H), 
4.03 (s, 3H), 3.40-3.31 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 170.5, 170.2, 158.0, 149.8, 
148.8, 135.9, 135.6, 131.7, 131.4, 130.5, 126.4, 124.6, 124.2, 123.9, 123.4, 122.1, 118.2, 
117.3, 115.4, 115.1, 105.2, 104.3, 103.9, 56.2, 56.1, 55.7, 53.1, 47.9, 42.7, 39.9, 39.8, 39.4, 
30.7, 29.0; ESI-HRMS ([M + H]+) calcd for C26H28NO4 418.2018, found 418.2024. 
47c: mp 73-75 °C; [α]23D= 144.6 ° (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3, 
compound rotameric at rt): δ 7.94-7.75 (m, 3H), 7.31-7.22 (m, 2H), 5.98-5.76 (m, 3H), 5.19-
4.99 (m, 5H), 4.84-4.53 (d, J = 17.1 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.00 (s, 3H), 3.33 (d, 
J = 18.6 Hz, 2H), 2.65 (q, J = 7.2 Hz, 2), 2.55-2.46 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 
171.8, 171.5, 158.0, 149.7, 148.8, 137.6, 136.1, 135.8, 130.5, 126.7, 126.4, 124.5, 124.4, 
124.0, 123.9, 123.5, 123.1, 122.0, 117.3, 117.1, 115.5, 115.1, 105.2, 104.3, 103.9, 56.2, 
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56.1, 55.7, 52.9, 47.8, 42.5, 39.9, 33.6, 33.0, 30.8, 29.5, 29.0; ESI-HRMS ([M + H]+) calcd 
for C27H30NO4 432.2175, found 432.2184. 
General procedures for the synthesis of 48a-c: Compounds 47a-c were dissolved 
in degassed CH2Cl2 under N2, to which Grubb’s 2nd generation catalyst in CH2Cl2 was added 
in one portion. The reaction was stirred at reflux for 2 h or monitored by TLC. Compounds 
48a-c were isolated by column chromatography eluting with CH2Cl2/MeOH. Yield: 70% - 
85%. 
48a: mp 105-107 °C; [α]23D= -191.8 ° (c 0.55, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
7.90 (s, 1H), 7.89 (d, J = 3.3 Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.42 (d, J = 5.7 Hz, 1H), 7.25 
(s, 1H), 7.24 (dd, J = 9.0 Hz, J = 2.7Hz, 1H), 6.39 (d, J = 6.0Hz, 1H), 5.49 (d, J = 17.1 Hz, 
1H), 4.75 (d, J = 17.7 Hz, 1H), 4.35 (dd, J = 12 Hz, J = 5.4 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 
3H), 4.02 (s, 3H), 3.62 (dd, J = 15.9 Hz, J = 4.5 Hz, 1H), 2.71 (dd, J = 15.0 Hz, 12.0 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ 169.5, 158.2, 149.8, 149.0, 147.4, 130.6, 128.6, 126.2, 124.4, 
124.1, 123.9, 123.4, 122.4, 115.4, 105.2, 104.2, 104.0, 57.7, 56.2, 56.1, 55.7, 40.2, 30.0; 
ESI-HRMS ([M + H]+) calcd for C23H22NO4 376.1549, found 376.1559. 
48b: mp 238-240 °C; [α]23D= -216.4 ° (c 0.58, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
7.93 (d, J = 9.3 Hz, 1H), 7.90-7.89 (m, 2H), 7.23-7.21 (m, 2H), 6.07 (d, J = 17.7 Hz, 1H), 
6.03-5.90 (m, 2H), 4.49 (d, J = 17.4 Hz, 1H), 4.40-4.36 (m, 1H), 4.11 (s, 3H), 4.05 (s, 3H), 
4.02 (s, 3H), 3.35 (dd, J = 15.6 Hz, J = 2.4 Hz, 1H), 3.13 (brs, 2H), 3.04-2.99 (m, 1H); 13C 
NMR (75 MHz, CDCl3): δ 166.4, 158.1, 149.7, 148.8, 130.5, 126.2, 125.1, 124.7, 124.6, 
123.9, 123.8, 123.5, 122.2, 115.2, 105.1, 104.1, 103.9, 56.2, 56.1, 55.7, 54.6, 42.8, 34.8, 
32.1; ESI-HRMS ([M + H]+) calcd for C24H24NO4 390.1705, found 390.1706. 
48c: mp 205-207 °C; [α]23D= 81.9 ° (c 1.50, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
8.08 (d, J = 9.0 Hz, 1H), 7.93 (s, 1H), 7.90 (d, J = 2.7 Hz, 1H), 7.36 (s, 1H), 7.25 (dd, J = 9.0 
Hz, J = 2.4 Hz, 1H), 5.75-5.70 (m, 1H), 5.59-5.54 (m, 1H), 5.32 (d, J = 15.9 Hz, 1H), 4.97 (d, 
J = 16.2 Hz, 1H), 4.89 (m, 1H), 4.11 (s, 3H), 4.08 (s, 3H), 4.01 (s, 3H), 3.37 (dd, J = 15.3 Hz, 
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J = 5.4 Hz, 1H), 3.25 (dd, J = 15.3 Hz, J = 8.1 Hz, 1H), 3.10 (dt, J = 13.2 Hz, J = 8.1 Hz, 1H), 
2.56 (dt, J = 13.5 Hz, 4.8 Hz, 1H), 2.42 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 173.8, 158.0, 
149.9, 148.9, 131.6, 130.6, 130.5, 128.2, 125.8, 125.7, 125.0, 124.0, 123.2, 115.4, 105.1, 
104.3, 103.7, 56.2, 56.1, 55.7, 51.6, 40.9, 35.1, 31.7, 25.2; ESI-HRMS ([M + H]+) calcd for 
C25H26NO4 404.1862, found 404.1856. 
General procedure for the synthesis of 49a-c: Compounds 48a-c were dissolved 
in MeOH, to which Pd/C was added. The mixture was hydrogenated under H2 at 50 psi 
overnight. The catalyst was removed by filtration and column chromatography eluting with 
CH2Cl2/MeOH gave 49a-c. Yield: 90%.  
49a: mp 185-187 °C; [α]23D= -134.4 ° (c 0.45, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
7.84 (s, 1H), 7.83 (d, J = 3.0 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.7 
Hz, 1H), 7.19 (s, 1H), 5.29 (d, J = 17.4 Hz, 1H), 4.50 (d, J = 17.1 Hz, 1H), 4.08 (s, 3H), 4.03 
(s, 3H), 4.00 (s, 3H), 3.91-3.84 (m, 1H), 3.36 (dd, J = 15.6 Hz, J = 4.2 Hz, 1H), 2.73 (dd, J = 
15.6 Hz, 11.1 Hz, 1H), 2.59-2.44 (m, 3H), 2.05-2.44 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 
174.2, 158.1, 149.7, 148.8, 130.4, 126.4, 124.4, 124.0, 123.9, 123.8, 123.4, 115.2, 105.1, 
104.2, 104.0, 56.1, 56.0, 55.7, 53.3, 41.1, 33.5, 30.3, 25.5; ESI-HRMS ([M + H]+) calcd for 
C23H24NO4 378.1705, found 378.1713. 
49b: mp 257-259 °C; [α]23D= -183.6 ° (c 1.9, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
7.88 (d, J = 9.0 Hz, 1H), 7.86 (s, 1H), 7.85 (d, J = 3.0 Hz, 1H), 7.21 (dd, J = 9.0 Hz, J = 2.7 
Hz, 1H), 7.16 (s, 1H), 5.88 (d, J = 17.4 Hz, 1H), 4.41 (d, J = 17.4 Hz, 1H), 4.09 (s, 3H), 4.04 
(s, 3H), 4.00 (s, 3H), 3.79-3.74 (m, 1H), 3.11-3.02 (m, 2H), 2.52 (t, J = 6.0 Hz, 2H), 2.28-
2.20 (m, 1H), 2.05-1.96 (m, 1H), 1.94-1.84 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 169.7, 
157.9, 149.6, 148.7, 130.4, 126.2, 124.7, 124.6, 124.0, 123.7, 123.5, 115.1, 105.1, 104.1, 
103.9, 56.2, 56.1, 55.7, 52.7, 43.4, 34.0, 33.1, 29.2, 18.6; ESI-HRMS ([M + H]+) calcd for 
C24H26NO4 392.1862, found 392.1865. 
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49c: mp 232-234 °C; [α]23D= 47.2 ° (c 0.97, CHCl3); 1H NMR (300 MHz, CDCl3): δ 
8.12 (d, J = 9.0 Hz, 1H), 7.95 (s, 1H), 7.92 (d, J = 2.4 Hz, 1H), 7.38 (s, 1H), 7.26 (dd, J = 9.0 
Hz, J = 2.4 Hz, 1H), 5.23 (d, J = 15.9 Hz, 1H), 4.97 (d, J = 15.9 Hz, 1H), 4.12 (s, 3H), 4.09 (s, 
3H), 4.02 (s, 3H), 3.96-3.92 (m, 1H), 3.39 (dd, J = 15.0 Hz, J = 5.4 Hz, 1H), 3.15 (dd, J = 
15.3 Hz, 6.9 Hz, 1H), 2.66-2.64 (m, 2H), 1.88-1.84 (m, 3H), 1.65-1.56 (m, 3H); 13C NMR (75 
MHz, CDCl3): δ 175.0, 158.0, 149.9, 148.9, 130.4, 127.4, 126.0, 125.7, 125.1, 124.1, 123.2, 
115.4, 105.1, 104.4, 103.8, 56.2, 56.1, 55.7, 54.3, 40.0, 37.0, 34.4, 32.4, 28.2, 23.1; ESI-
HRMS ([M + H]+) calcd for C25H28NO4 406.2018, found 406.2024. 
General procedure for the synthesis of R-antofine (50a), R-cryptopleurine (50b), 
and compound 50c: The amides 49a-c and LiAlH4 (2 equiv.) were suspended in THF (15 
mL), which was stirred for 2-3 h. Water was then added to quench the reaction, followed by 
aq. NaOH (1N, 1mL) and H2O (1 mL). The mixture was filtered and then extracted with 
CHCl3 and dried over MgSO4. Column chromatography eluting with CH2Cl2/MeOH gave the 
target products. Yield: 70% -80%. 
R-Antofine (50a): mp 204-206 °C (lit.9 206-211 °C); [α]23D= -129.2 ° (c 0.48, CHCl3, 
lit.9 [α]19D= -125.2 °); IR (FT-IR ATR, cm-1) 2830, 1616, 1507, 1259, 1030; 1H NMR (300 MHz, 
CDCl3): δ 7.92 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 7.32 (s, 1H), 7.20 
(dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.69 (d, J = 15.9 Hz, 1H), 4.11 (s, 3H), 4.07 (s, 3H), 4.02 (s, 
3H), 3.69 (d, J = 14.7 Hz, 1H), 3.46 (dt, J = 8.7 Hz, J = 1.8 Hz, 1H), 3.35 (dd, J = 16.2 Hz, J 
= 2.4 Hz, 1H), 2.90 (dd, J = 15.6 Hz, J = 10.8 Hz, 1H), 2.51-2.41 (m, 2H), 2.26-2.21 (m, 1H), 
2.05-1.91 (m, 2H), 1.83-1.74 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 157.6, 149.6, 148.5, 
130.3, 127.3, 126.8, 125.7, 124.4, 124.3, 123.7, 115.0, 104.9, 104.2, 104.1, 60.4, 56.2, 56.0, 
55.7, 55.2, 54.0, 33.9, 31.5, 21.8; ESI-HRMS ([M + H]+) calcd for C23H26NO3 364.1913, 
found 364.1918. 
R-Cryptopleurine (50b): mp 201-203 °C (lit.9 195-197 °C); [α]23D= -108.8° (c 0.64, 
CHCl3, lit.9 [α]21D= -108.7°); IR (FT-IR ATR, cm-1) 2828, 1507, 1472, 1255, 1230, 1205, 1036, 
72 
831; 1H NMR (300 MHz, CDCl3): δ 7.87 (s, 1H), 7.86 (d, J = 3.0 Hz, 1H), 7.76 (d, J = 9.0 Hz, 
1H), 7.20 (s, 1H), 7.17 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.39 (d, J = 15.6 Hz, 1H), 4.08 (s, 
3H), 4.04 (s, 3H), 3.99 (s, 3H), 3.56 (d, J = 15.3 Hz, 1H), 3.24 (d, J = 11.1 Hz, 1H), 3.00 (dd, 
J = 16.5 Hz, J = 3.0 Hz, 1H), 2.82 (dd, J = 15.9 Hz, J = 10.5 Hz, 1H), 2.33-2.21 (m, 2H), 
2.01-1.97 (m, 1H), 1.89-1.84 (m, 1H), 1.78 (m, 2H), 1.52-1.45 (m, 2H); 13C NMR (75 MHz, 
CDCl3): δ 157.5, 149.5, 148.4, 130.2, 126.6, 125.7, 124.6, 124.2, 123.8, 123.5, 114.9, 104.8, 
104.0 (2×C), 57.6, 56.4, 56.2, 56.1, 56.0, 55.6, 34.9, 33.9, 26.1, 24.5; ESI-HRMS ([M + H]+) 
calcd for C24H28NO3 378.2069, found 378.2077. 
E7 (50c):  mp 193-195 °C; [α]23D= -82.6 ° (c 0.38, CHCl3); IR (FT-IR ATR, cm-1) 2826, 
1609, 1507, 1472, 1418, 1257, 1037; 1H NMR (300 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 
2.4 Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.27 (s, 1H), 7.19 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.42 
(d, J = 15.0 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.05 (d, J = 15.3 Hz, 1H), 4.01 (s, 3H), 3.07-
2.93 (m, 4H), 2.82-2.77 (m, 1H), 1.95-1.59 (m, 8H); 13C NMR (75 MHz, CDCl3): δ 157.5, 
149.5, 148.4, 130.2, 127.1, 126.0, 124.3 (2×C), 124.1, 123.6, 115.0, 104.9, 104.2, 104.0, 
60.6, 57.3, 56.2, 56.1, 55.7, 55.4, 35.8, 33.9, 29.2, 27.8, 24.7; ESI-HRMS ([M + H]+) calcd 
for C25H30NO3 392.2226, found 392.2225. 
E8 (50d):  mp 168-170 °C; [α]23D= -106.1 ° (c 0.26, CHCl3); 1H NMR (400 MHz, 
CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.8 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 7.28 (s, 1H), 7.19 
(dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 4.35 (d, J = 15.6 Hz, 1H), 4.20 (d, J = 16.0 Hz, 1H), 4.10 (s, 
3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.16-3.06 (m, 2H), 3.04-2.88 (m, 3H), 2.03-1.99 (m, 1H), 
1.91-1.85 (m, 3H), 1.80-1.77 (m, 2H), 1.67-1.56 (m, 4H); ESI MS m/z 406.10 (M+H)+. 
51:  Similar procedure as 47a-c. mp 74-76 °C; [α]23D= 71.5 ° (c 1.16, CHCl3); 1H 
NMR (400 MHz, CDCl3, compound rotameric at rt): δ 7.89-7.84 (m, 3H), 7.28 (s, 1H), 7.21 
(dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 5.88-5.61 (m, 2H), 5.20-5.10 (m, 3H), 4.64 (d, J = 3.2 Hz, 
1H), 4.54 (m, 1H), 4.46 (d, J = 3.2 Hz), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.73 (s, 3H), 
3.43-3.28 (m, 2H);  13C NMR (100 MHz, CDCl3): δ 165.9, 162.6, 157.9, 157.2, 149.7, 148.8, 
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135.9, 130.4, 126.5, 124.3, 123.8, 123.7, 123.3, 117.7, 115.2, 105.0, 104.1, 103.9, 56.1, 
56.0, 55.6, 55.3, 53.8, 39.6, 36.5, 31.5, 30.3; ESI-HRMS ([M + H]+) calcd for C26H27NO5 
433.1889, found 434.1963. 
52:  Similar procedure as 48a-c. mp 135-137 °C; [α]23D= -235 ° (c 1.11, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.80 (s, 1H), 7.79 (d, J = 2.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 
7.20-7.17 (m, 2H), 6.00 (d, J = 2.4 Hz, 1H), 5.37 (d, J = 17.6 Hz, 1H), 4.65 (d, J = 17.2 Hz, 
1H), 4.16-4.12 (m, 1H), 4.10 (s, 3H), 4.03 (s, 3H), 4.00 (s, 3H), 3.86 (s, 3H), 3.52 (dd, J = 
11.6 Hz, J = 4.8 Hz, 1H), 2.53 (dd, J = 15.6 Hz, J = 11.6 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ 163.9, 158.0, 153.1, 149.5, 148.7, 130.4, 126.0, 124.1, 124.0, 123.2, 123.2, 122.4, 
115.3, 108.7, 104.9, 104.0, 103.9, 57.5, 56.1, 56.0, 55.6, 52.4, 40.4, 31.4; ESI-HRMS ([M + 
H]+) calcd for C24H23NO5 405.1567, found 406.1667. 
53:  Similar procedure as 49a-c. mp 202-204 °C; [α]23D= -97.0 ° (c 0.47, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.91 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 
7.33 (s, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.83 (s, 1H), 4.52 (d, J = 14.4 Hz, 1H), 
4.10 (s, 3H), 4.06 (s, 3H), 4.05 (d, J = 14.4 Hz, 1H), 4.01 (s, 3H), 3.83 (d, J = 7.2 Hz, 1H), 
3.72 (s, 3H), 3.58 (m, 2H), 3.32 (d, J = 15.2 Hz, 1H), 3.02 (m, 1H); 13C NMR (100 MHz, 
CDCl3): δ 159.7, 157.7, 149.6, 148.6, 130.2, 127.7, 127.6, 125.8, 124.5, 124.4, 123.7, 115.1, 
104.8, 104.3, 104.0, 95.3, 63.7, 57.8, 57.0, 56.2, 56.0, 55.7, 51.8, 33.8; ESI-HRMS ([M + H]+) 
calcd for C24H25NO4 391.1784, found 392.1865. 
S-12-Oxo-antofine (54):  Compound 53 (300 mg) was refluxed in HCl/THF for 2 h 
before the solvent was evaporated. NaOH was used for neutralization and CH2Cl2 used for 
extraction. Chromatography gave 200 mg of light yellow solid (68%). mp 240-242 °C; [α]23D= 
-34.7 ° (c 0.91, CHCl3); IR (FT-IR ATR, cm-1) 2833, 1751, 1609, 1510, 1260, 1234, 1208, 
1202, 1126, 867, 777; 1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 
7.78 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 7.22 (dd, J = 9.2 Hz, J = 2.6 Hz, 1H), 4.70 (d, J = 14.8 
Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.84 (d, J = 15.2 Hz, 1H), 3.78 (d, J = 16.8 
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Hz, 1H), 3.43 (d, J = 13.2 Hz, 1H), 3.07-3.01 (m, 2H), 2.98 (d, J = 16.4 Hz, 1H), 2.76 (dd, J = 
17.6 Hz, J = 5.2 Hz, 1H), 2.43 (dd, J = 17.6 Hz, J = 10.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ 212.4, 157.7, 149.5, 148.6, 130.2, 126.6, 125.7, 124.5, 124.0, 123.7, 123.6, 115.1, 
104.7, 103.8, 103.7, 63.1, 57.9, 56.0, 55.9, 53.4, 44.7, 33.2; ESI-HRMS ([M + H]+) calcd for 
C23H23NO4 377.1627, found 378.1704. 
General procedures for the synthesis of E-ring opened analogs (55-63): The 
intermediate 44 (176 mg, 0.50 mmol) was suspended in MeOH, to which RCHO (2 equiv.), 
HOAc (3 equiv.), and NaBH3CN (63 mg, 1 mmol) were added. The mixture was stirred for 2-
8 h as monitored by TLC. Then sat. NaHCO3 was added and the solvent was removed in 
vacuo. The white solid was then suspended in water, filtered, and washed sequentially with 
cold water, cold MeOH, and ether to afford the goal products 55-63 as white solids. Yield: 
60-80%.  
(S)-(N-Ethyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-
yl)methanol (55): 1H NMR (300 MHz, CDCl3): δ 7.91-7.90 (m, 2H), 7.82 (d, J = 9.0 Hz, 1H), 
7.27 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.39 (d, J = 16.8 Hz, 1H), 4.15 (d, J = 
16.8 Hz, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.02 (s, 3H), 3.77-3.73 (m, 2H), 3.41-3.35 (m, 1H), 
3.13 (dd, J = 16.8 Hz, J = 6.0 Hz, 1H), 2.85 (dd, J = 17.4 Hz, J = 5.4 Hz, 1H), 2.78 (q, J = 
6.9 Hz, 2H), 1.22 (t, J = 6.9 Hz, 3H); ESI MS m/z 382.10 (M+H)+. 
(S)-(N-Propyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-
yl)methanol (56): 1H NMR (300 MHz, CDCl3): δ 7.91-7.90 (m, 2H), 7.82 (d, J = 9.0 Hz, 1H), 
7.28 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.39 (d, J = 17.1 Hz, 1H), 4.16 (d, J = 
17.1 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.73 (d, J = 6.9 Hz, 2H), 3.44-3.36 (m, 
1H), 3.13 (dd, J = 16.8 Hz, J = 5.7 Hz, 1H), 2.81 (dd, J = 17.1 Hz, J = 5.4 Hz, 1H), 2.64 (t, J 
= 7.5 Hz, 2H), 1.70-1.61 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H); ESI MS m/z 396.10 (M+H)+. 
(S)-(N-Cyclopentyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-
3-yl)methanol (57): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.83 (d, J = 9.0 Hz, 
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1H), 7.29 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.37 (d, J = 17.4 Hz, 1H), 4.25 (d, J 
= 17.7 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.77-3.71 (m, 2H), 3.66-3.58 (m, 1H), 
3.33-3.17 (m, 2H), 2.69 (d, J = 17.1 Hz, 1H), 2.02 (m, 1H), 1.95-1.89 (m, 1H), 1.72 (m, 2H), 
1.62-1.52 (m, 4H); ESI MS m/z 422.10 (M+H)+. 
(S)-(N-Cyclopentylmethyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]- 
isoquinolin-3-yl)methanol (58): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.83 (d, J 
= 8.7 Hz, 1H), 7.28 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.41 (d, J = 17.4 Hz, 1H), 
4.18 (d, J = 17.4 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.70 (d, J = 7.5 Hz, 2H), 
3.47-3.39 (m, 1H), 3.13 (dd, J = 16.8 Hz, J = 6.0 Hz, 1H), 2.75 (dd, J = 17.1 Hz, J = 4.8 Hz, 
1H), 2.57 (d, J = 7.8 Hz, 2H), 2.27-2.17 (m, 1H), 1.81 (m, 2H), 1.61-1.56 (m, 4H), 1.25-1.19 
(m, 2H); ESI MS m/z 436.10 (M+H)+. 
(S)-(N-Isobutyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-
yl)methanol (59): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.82 (d, J = 9.0 Hz, 1H), 
7.29 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.38 (d, J = 17.1 Hz, 1H), 4.14 (d, J = 
17.1 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.70 (d, J ＝ 7.5 Hz, 2H), 3.44-3.36 (m, 
1H), 3.14 (dd, J = 17.1 Hz, J = 6.3 Hz, 1H), 2.76 (dd, J = 16.8 Hz, J = 5.4 Hz, 1H), 2.43 (dd, 
J = 7.5 Hz, 2H), 1.97-1.88 (m, 1H), 0.97-0.94 (t, J = 3.6 Hz, 6H); ESI MS m/z 410.10 (M+H)+. 
(S)-(N-Cyclobutyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-
3-yl)methanol (60): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.82 (d, J = 9.0 Hz, 
1H), 7.28 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.17 (m, 2H), 4.11 (s, 3H), 4.06 (s, 
3H), 4.02 (s, 3H), 3.70-3.57 (m, 2H), 3.49-3.39 (m, 2H), 3.18 (dd, J = 17.1 Hz, J = 6.3 Hz, 
1H), 2.68 (d, J = 17.1 Hz, 1H), 2.11 (m, 2H), 2.01-1.89 (m, 2H), 1.76-1.54 (m, 2H); ESI MS 
m/z 408.10 (M+H)+. 
(S)-(N-Cyclopropylmethyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]-
isoquinolin-3-yl)methanol (61): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.84 (d, J 
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= 9.0 Hz, 1H), 7.27 (s, 1H), 7.23 (dd, J = 9.3 Hz, J = 2.7 Hz, 1H), 4.53 (d, J = 16.8 Hz, 1H), 
4.30 (d, J = 17.4 Hz, 1H), 4.11 (s, 3H), 4.05 (s, 3H), 4.02 (s, 3H), 3.75-3.71 (m, 2H), 3.51-
3.47 (m, 1H), 3.11 (dd, J = 17.4 Hz, J = 5.7 Hz, 1H), 2.81 (dd, J = 16.8 Hz, J = 5.1 Hz, 1H), 
2.61-2.58 (m, 2H), 1.01 (m, 1H), 0.58-0.53 (m, 2H), 0.11-0.09 (m, 2H); ESI MS m/z 408.10 
(M+H)+. 
(R)-(N-Propyl-6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-
yl)methanol (62): 1H NMR (300 MHz, CDCl3): δ 7.92-7.91 (m, 2H), 7.82 (d, J = 9.0 Hz, 1H), 
7.28 (s, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.39 (d, J = 17.1 Hz, 1H), 4.15 (d, J = 
17.1 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.73 (d, J = 7.2 Hz, 2H), 3.42-3.35 (m, 
1H), 3.13 (dd, J = 17.4 Hz, J = 5.7 Hz, 1H), 2.81 (dd, J = 17.1 Hz, J = 5.1 Hz, 1H), 2.64 (t, J 
= 7.5 Hz, 2H), 1.68-1.60 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H); ESI MS m/z 396.10 (M+H)+. 
General procedures for the synthesis of 12N-substituted-12-aza-antofine (64-
75): The aldehyde was obtained using the same procedure as for compound 46. A variety of 
amines were added to the aldehyde in MeOH, followed by addition of HOAc and NaBH3CN, 
which was stirred at r.t. for 4 h. Sat. NaHCO3 was added to quench the reaction and CH2Cl2 
was used for extraction. The residue was purified through a quick column and TFA was 
used to remove the Boc group. Then TFA was removed by evaporation and the residue was 
dissolved in CH2Cl2 (10 ml), to which K2CO3 (100 mg) and MgSO4 (0.5 g) were added, 
followed by HCHO (37%, 0.1 ml). The mixture was stirred at r.t. overnight. Chromatography 
(MeOH/CH2Cl2) gave from light yellow to white solids. Yield: 40% - 80%.  
(S)-12N-Benzyl-12-aza-antofine (64): light yellow solid; mp 113-115 °C; [α]23D= -
31.7 ° (c 0.48, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.87-7.86 (m, 2H), 7.67 (d, J = 9.0 Hz, 
1H), 7.47-7.40 (m, 5H), 7.22 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.14 (s, 1H), 4.59 (d, J = 14.4 
Hz, 1H), 4.31-4.20 (m, 3H), 4.10 (s, 3H), 4.06-3.87 (m, 4H), 4.03 (s, 3H), 4.01 (s, 3H), 3.31-
3.25 (m, 1H), 3.07 (m, 2H); ESI MS m/z 455.15 (M+H)+. 
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(S)-12N-Isobutyl-12-aza-antofine (65): yellow solid; mp 93-95 °C; [α]23D= -84.0 ° (c 
0.37, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.88-7.86 (m, 2H), 7.74 (d, J = 9.0 Hz, 1H), 
7.23 (s, 1H), 7.19 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.54 (d, J = 14.7 Hz, 1H), 4.14 (d, J = 5.4 
Hz, 1H), 4.10 (s, 3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.76 (d, J = 15.0 Hz, 1H), 3.62 (d, J = 5.1 
Hz, 1H), 3.41-3.38 (m, 1H), 3.26-3.19 (m, 1H), 2.95-2.83 (m, 3H), 2.58 (d, J = 7.2Hz, 2H), 
1.84-1.75 (m, 1H), 1.00-0.98 (d, J = 6.0 Hz, 6H); ESI MS m/z 421.10 (M+H)+. 
(S)-12N-Propyl-12-aza-antofine (66): light yellow solid; mp 155-157 °C; [α]23D= -
75.4 ° (c 0.50, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 90 (s, 1H), 7.88 (d, J = 2.7 Hz, 1H), 
7.76 (d, J = 9.0 Hz, 1H), 7.26 (s, 1H), 7.20 (dd, J = 9.3 Hz, J = 2.4 Hz, 1H), 4.56 (d, J = 14.4 
Hz, 1H), 4.16 (d, J = 5.1 Hz, 1H), 4.11 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.77 (d, J = 14.7 
Hz, 1H), 3.62 (d, J = 4.8 Hz, 1H), 3.44-3.40 (m, 1H), 3.30-3.27 (m, 1H), 3.01-2.80 (m, 3H), 
2.72 (t, J = 7.5Hz, 2H), 1.64-1.54 (m, 2H), 0.98 (t, J = 7.5 Hz, 3H); ESI MS m/z 407.15 
(M+H)+. 
(S)-12N-(2’-Phenylethyl)-12-aza-antofine (67): light yellow solid; mp 85-87 °C; 
[α]23D= -63.2 ° (c 0.28, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.88-7.87 (m, 2H), 7.74 (d, J = 
9.0 Hz, 1H), 7.34-7.22 (m, 6H), 7.21 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.55 (d, J = 14.4 Hz, 
1H), 4.23(d, J = 5.1 Hz, 1H), 4.10 (s, 3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.78 (d, J = 14.7 Hz, 
1H), 3.69 (d, J = 5.4 Hz, 1H), 3.54-3.52 (m, 1H), 3.29-3.22 (m, 1H), 3.10-3.05 (m, 2H), 2.83-
2.78 (m, 5H); ESI MS m/z 469.20 (M+H)+. 
(S)-12N-(2’-Hydroxy)ethyl-12-aza-antofine (68): white solid; mp 210-212 °C; 
[α]23D= -57.8 ° (c 0.36, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 90-7.89 (m, 2H), 7.75 (d, J = 
9.0 Hz, 1H), 7.24-7.22 (m, 2H), 4.62 (d, J = 15.0 Hz, 1H), 4.39 (d, J = 6.3 Hz, 1H), 4.11 (s, 
3H), 4.03 (s, 3H), 4.02 (s, 3H), 3.83 (d, J = 15.0 Hz, 1H), 3.81-3.77 (t, J = 5.1 Hz, 2H), 3.71 
(d, J = 5.4 Hz, 1H), 3.64 (m, 1H), 3.41-3.29 (m, 1H), 3.16-3.11 (m, 3H), 3.02-2.95 (m, 2H); 
ESI MS m/z 409.15 (M+H)+. 
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(S)-12N-Phenyl-12-aza-antofine (69): white solid; mp 244-246 °C; [α]23D= -121.8 ° 
(c 0.34, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.88-7.86 (m, 2H), 7.77 (d, J = 9.3 Hz, 1H), 
7.28 (t, J = 7.5 Hz, 2H), 7.25 (s, 1H), 7.21 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 6.74 (t, J = 7.5Hz, 
1H), 6.56 (d, J = 8.1 Hz, 2H), 4.73 (d, J = 3.6 Hz, 1H), 4.65 (d, J = 14.4 Hz, 1H), 4.09 (s, 3H), 
4.05 (s, 3H), 4.00 (s, 3H), 3.97 (d, J = 3.3 Hz, 1H), 3.89 (d, J = 14.7 Hz, 1H), 3.74 (dd, J = 
7.8 Hz, J = 5.4 Hz, 1H), 3.43-3.31 (m, 2H), 3.07-3.02 (m, 2H); ESI MS m/z 441.10 (M+H)+. 
(S)-12N-Cyclopropyl-12-aza-antofine (70): white solid; mp 204-206 °C; [α]23D= -
87.9 ° (c 0.34, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 88 (s, 1H), 7.86 (d, J = 2.7 Hz, 1H), 
7.76 (d, J = 9.0 Hz, 1H), 7.25 (s, 1H), 7.18 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.55 (d, J = 14.7 
Hz, 1H), 4.29 (d, J = 5.4 Hz, 1H), 4.09 (s, 3H), 4.04 (s, 3H), 4.00 (s, 3H), 3.73 (d, J = 14.7 
Hz, 1H), 3.59 (d, J = 5.4 Hz, 1H), 3.44 (dd, J = 8.7 Hz, J = 6.0 Hz, 1H), 3.26 (d, J = 15.3 Hz, 
1H), 2.99-2.92 (m, 2H), 2.88-2.81 (m, 1H), 2.22-2.19 (m, 1H), 0.53-0.45 (m, 4H); ESI MS 
m/z 405.10 (M+H)+. 
(S)-12N-Methyl-12-aza-antofine (71): white solid; mp 182-184 °C; [α]23D= -45.0 ° (c 
0.34, CHCl3) ; IR (FT-IR ATR, cm-1) 2832, 1616, 1512, 1257, 1032; 1H NMR (300 MHz, 
CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.7 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.26 (s, 1H), 7.19 
(dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.57 (d, J = 14.7 Hz, 1H), 4.11 (d, J = 5.1 Hz, 1H), 4.10 (s, 
3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.80 (d, J = 15.0 Hz, 1H), 3.62 (d, J = 5.1 Hz, 1H), 3.41 (dd, J 
= 8.4 Hz, J = 5.1 Hz, 1H), 3.48 (d, J = 12.9 Hz, 1H), 3.01-2.95 (m, 2H), 2.85-2.79 (m, 1H), 
2.62 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 157.9, 149.7, 148.7, 130.4, 126.9, 125.8, 124.6, 
124.3, 124.0, 123.8, 115.2, 104.9, 104.1, 104.0, 78.0, 61.0, 59.2, 56.2, 56.1, 55.7, 50.4, 43.5, 
31.0; ESI-HRMS ([M + H]+) calcd for C23H26N2O3 378.1943, found 379.2025. 
(S)-12N-Dimethylamino-12-aza-antofine (72): white solid; mp 113-115 °C; [α]23D= -
71.9 ° (c 0.31, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.91 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 
7.77 (d, J = 9.0 Hz, 1H), 7.29 (s, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.56 (d, J = 14.7 
Hz, 1H), 4.40 (d, J = 6.6 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.70 (d, J = 14.7 
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Hz, 1H), 3.56 (d, J = 6.6 Hz, 1H), 3.51 (dd, J = 9.0 Hz, J = 5.4 Hz, 1H), 3.32 (m, 1H), 3.07-
2.95 (m, 2H), 2.84-2.78 (m, 1H), 2.50 (s, 6H); ESI MS m/z 408.10 (M+H)+. 
(R)-12N-Benzyl-12-aza-antofine (73): light yellow solid; mp 95-97 °C; [α]23D= 28.6 ° 
(c 0.28, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.89 (s, 1H), 7.88 (d, J = 2.7 Hz, 1H), 7.74 (d, 
J = 9.0 Hz, 1H), 7.44-7.42 (m, 2H), 7.38-7.27 (m, 3H), 7.25 (s, 1H), 7.19 (dd, J = 9.0 Hz, J = 
2.7 Hz, 1H), 4.55 (d, J = 14.4 Hz, 1H), 4.17 (d, J = 5.4 Hz, 1H), 4.10 (s, 3H), 4.03 (s, 3H), 
4.01 (s, 3H), 3.96 (s, 2H), 3.78 (d, J = 14.4 Hz, 1H), 3.60 (d, J = 5.4 Hz, 1H), 3.40-3.38 (m, 
1H), 3.29-3.26 (m, 1H), 3.00-2.85 (m, 3H); ESI MS m/z 455.20 (M+H)+. 
(R)-12N-Dimethylamino-12-aza-antofine (74): white solid; mp 77-79 °C; [α]23D= 
54.3 ° (c 0.93, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 
7.76 (d, J = 9.2 Hz, 1H), 7.27 (s, 1H), 7.19 (dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 4.55 (d, J = 14.4 
Hz, 1H), 4.39 (d, J = 6.4 Hz, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.69 (d, J = 14.8 
Hz, 1H), 3.55 (d, J = 6.4 Hz, 1H), 3.50 (dd, J = 8.8 Hz, J = 6.0 Hz, 1H), 3.30 (dd, J = 15.2 Hz, 
J = 2.4 Hz, 1H), 3.03 (t, J = 9.2 Hz, 1H), 3.01-2.95 (m, 1H), 2.81-2.77 (m, 1H), 2.50 (s, 6H); 
ESI MS m/z 408.05 (M+H)+. 
(R)-12N-Methyl-12-aza-antofine (75): light yellow solid; mp 147-149 °C; [α]23D= 
60.3 ° (c 1.17, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.80 (s, 2H), 7.65 (d, J = 8.7 Hz, 1H), 
7.17 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.11 (s, 1H), 4.47 (d, J = 14.7 Hz, 1H), 4.22 (d, J = 6.0 
Hz, 1H), 4.08 (s, 3H), 4.01 (s, 3H), 4.00 (s, 3H), 3.70-3.64 (m, 2H), 3.58-3.55 (m, 1H), 3.14 
(d, J = 11.4 Hz, 1H), 2.98-2.83 (m, 3H), 2.75 (s, 3H); ESI MS m/z 379.15 (M+H)+. 
 (S,E/Z)-6,7,10-Trimethoxy-3-(2-methoxyvinyl)-1,2,3,4-tetrahydrodibenzo[f,h]-
isoquinoline (76): N-Boc-alcohol 45 (1.812 g, 4 mmol) was dissolved in CH2Cl2 (50 ml) and 
Et3N (1.95 ml, 14 mmol) at 0 °C, to which Py•SO3 (2.23 g, 14 mmol) in 10 ml of DMSO was 
added dropwise. The ice bath was then removed and the mixture was stirred at r.t. until 
alcohol disappeared by TLC. HCl (1N) was added, and the organic layer was then separated 
and washed with sat. NaHCO3, brine, and dried over MgSO4. In another flask, 
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Ph3P+CH2OMeCl- (2.74 g, 8 mmol) was added to KOtBu (875 mg, 7.8 mmol) at 0 °C under 
N2, which was stirred for 0.5 h. The aldehyde in 20 ml of CH2Cl2 was added dropwise, 
followed by removal of ice bath. The reaction was kept for 2-3 h before sat. NH4Cl was 
poured into the mixture. CH2Cl2 was used for extraction and the organic layers were washed 
with sat. NaHCO3 and brine, dried over MgSO4. Chromatography afforded 1.5 g of 
compound 76 as a light yellow solid. Yield: 78% (Z/E = 1/2.5) for two steps. mp 150-152 °C; 
[α]23D= 108.1 ° (c 0.59, CHCl3); 1H NMR (400 MHz, CDCl3, E/Z = 2.5:1): δ 7.94-7.91 (m, 2H), 
7.88 (d, J = 9.2 Hz, 1H), 7.29 (s, 1H), 7.26-7.22 (m, 1H), 6.30 (d, J = 12.8 Hz, 0.68H, E 
isomer), 5.86 (dd, J = 6.4 Hz, J = 1.6 Hz, 0.28 Hz, Z isomer), 5.72 (m, 0.31H, Z isomer), 
5.30-5.25 (d, J = 16.8 Hz, 1H+0.67H, E isomer), 4.80 (dd, J = 12.8 Hz, J = 8.4 Hz, 0.71 H, E 
isomer ), 4.59 (d, J = 17.2 Hz, 1H), 4.42 (dd, J = 8.0 Hz, J = 6.4 Hz, 0.29H, Z isomer), 4.12-
4.11 (m, 3H), 4.05-4.04 (m, 3H), 4.03-4.02 (m, 3H), 3.62 (s, 0.71H, Z isomer), 3.44-3.32 (m, 
1H), 3.36 (s, 2H, E isomer), 3.13 (d, J = 16.0 Hz, 1H), 1.55 (s, 9H); ESI MS m/z 480.05 
(M+H)+. 
(S)-2-(6,7,10-Trimethoxy-1,2,3,4-tetrahydrodibenzo[f,h]isoquinolin-3-yl)-
acetaldehyde (77): Compound 76 (1.5 g, 3.12 mmol) was dissolved in THF (50 ml) and 
H2O (5 ml), to which Hg(OAc)2 (3.0 g, 9.36 mmol) was added at 0 °C. Then the ice bath was 
removed and the mixture was stirred overnight. Freshly prepared sat. KI (50 ml) was added 
dropwise at 0 °C for 10 min, and CH2Cl2 was used for extraction. The organic layers were 
collected and washed with brine, dried over MgSO4. Chromatography furnished 1.09 g of 
compound 77 as a light yellow foam. Yield: 75%. mp 98-100 °C; [α]23D= 94.4 ° (c 0.68, 
CHCl3); 1H NMR (400 MHz, CDCl3): δ 9.79 (s, 1H), 7.93 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 
7.85 (brs, 1H), 7.26-7.24 (m, 2H), 5.38-5.29 (m, 2H), 4.58 (d, J = 16.0 Hz, 1H), 4.11 (s, 3H), 
4.05 (s, 3H), 4.02 (s, 3H), 3.38 (dd, J = 16.0 Hz, J = 6.4 Hz, 1H), 3.12 (d, J = 16.4 Hz, 1H), 
2.70-2.59 (m, 2H), 1.53 (s, 9H); ESI MS m/z 466.10 (M+H)+, 488.15 (M+Na)+. 
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General procedures for the synthesis of 12N-substituted-12-aza-cryptopleurine 
(78-87): using similar procedures as compound 64-75. Yield: 50% - 70%. 
(S)-12N-(2’-Hydroxyethyl)-12-aza-cryptopleurine (78): white solid; mp 138-140 °C; 
[α]23D= -116.1 ° (c 0.28, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 88-7.87 (m, 2H), 7.73 (d, J 
= 9.0 Hz, 1H), 7.21 (s, 1H), 7.18 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.34 (d, J = 14.7 Hz, 1H), 
4.09 (s, 3H), 4.04 (s, 3H), 4.00 (s, 3H), 3.75-3.69 (m, 1H), 3.65 (t, J = 4.5 Hz, 1H), 3.57 (d, J 
= 14.7 Hz, 1H), 3.13-3.06 (m, 3H), 2.95-2.89 (m, 1H), 2.84-2.81 (m, 2H), 2.65-2.46 (m, 3H), 
1.92-1.86 (m, 2H); ESI MS m/z 423.10 (M+H)+. 
(S)-12N-Phenyl-12-aza-cryptopleurine (79): white solid; mp 225-227 °C; [α]23D= -
85.6 ° (c 0.25, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 88 (s, 2H), 7.78 (d, J = 9.0 Hz, 1H), 
7.27 (t, J = 7.8 Hz, 2H), 7.22-7.18 (m, 2H), 7.09 (d, J = 8.1 Hz, 2H), 6.87 (t, J = 6.9 Hz, 1H), 
4.77 (d, J = 11.1 Hz, 1H), 4.44 (d, J = 15.3 Hz, 1H), 4.09 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H), 
3.85 (d, J = 12.9 Hz, 1H), 3.63 (d, J = 15.3 Hz, 1H), 3.57 (d, J = 10.8 Hz, 1H), 3.19-3.06 (m, 
2H), 2.93-2.84 (m, 1H), 2.60 (m, 1H), 1.95-1.87 (m, 2H); ESI MS m/z 455.10 (M+H)+. 
(S)-12N-Isobutyl-12-aza-cryptopleurine (80): light yellow solid; mp 177-179 °C; 
[α]23D= -83.7 ° (c 0.30, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 86 (s, 2H), 7.70 (d, J = 9.3 
Hz, 1H), 7.18 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.17 (s, 1H), 4.42 (d, J = 15.9 Hz, 1H), 4.08 (s, 
3H), 4.02 (s, 3H), 3.99 (s, 3H), 3.65 (d, J = 14.7 Hz, 1H), 3.12-2.87 (m, 5H), 2.50-2.37 (m, 
2H), 2.36 (d, J = 7.2 Hz, 2H), 1.94-1.81 (m, 3H), 0.96 (d, J = 6.6 Hz, 6H); ESI MS m/z 
435.15 (M+H)+. 
(S)-12N-Benzyl-12-aza-cryptopleurine (81): white solid; mp 211-213 °C; [α]23D= -
80.5 ° (c 0.41, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 88-7.87 (m, 2H), 7.72 (d, J = 9.0 Hz, 
1H), 7.44-7.27 (m, 5H), 7.23(s, 1H), 7.16 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.32 (d, J = 15.3 
Hz, 1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.01 (m, 1H), 3.99 (s, 3H), 3.70 (s, 2H), 3.56 (d, J = 15.0 
Hz, 1H), 3.12-3.05 (m, 2H), 2.96-2.91 (m, 1H), 2.86 (d, J = 9.0 Hz, 1H), 2.44-2.29 (m, 2H), 
1.94-1.83 (m, 2H); ESI MS m/z 469.15 (M+H)+. 
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(S)-12N-Cyclopropyl-12-aza-cryptopleurine (82): white solid; mp 164-166 °C; 
[α]23D= -105.4 ° (c 0.50, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 88-7.87 (m, 2H), 7.74 (d, J 
= 9.0 Hz, 1H), 7.21 (s, 1H), 7.18 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.38 (d, J = 14.4 Hz, 1H), 
4.16 (d, J = 9.0 Hz, 1H), 4.08 (s, 3H), 4.04 (s, 3H), 3.99 (s, 3H), 3.59 (d, J = 15.3 Hz, 1H), 
3.20 (m, 1H), 3.09-3.01 (m, 2H), 2.94-2.85 (m, 1H), 2.58-2.41 (m, 2H), 1.99-1.94 (m, 1H), 
1.87-1.84 (m, 2H), 0.57-0.49 (m, 4H); ESI MS m/z 419.10 (M+H)+. 
(S)-12N-Dimethylamino-12-aza-cryptopleurine (83): white solid; mp 225-227 °C; 
[α]23D= -86.4 ° (c 0.50, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7. 89-7.88 (m, 2H), 7.76 (d, J = 
9.0 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 4.42 (d, J = 14.7 Hz, 1H), 
4.20 (d, J = 7.8 Hz, 1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.65 (d, J = 14.7 Hz, 1H), 
3.18-3.06 (m, 2H), 3.04 (d, J = 8.1 Hz, 1H), 2.88 (dd, J = 15.6 Hz, J = 10.5 Hz, 1H), 2.52 (s, 
6H), 2.48 (m, 1H), 2.31-2.24 (m, 1H), 2.01-1.83 (m, 2H); ESI MS m/z 422.15 (M+H)+. 
(R)-12N-Isobutyl-12-aza-cryptopleurine (84): light yellow solid; mp 175-177 °C; 
[α]23D= 85.0 ° (c 0.38, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7. 87 (m, 2H), 7.64 (d, J = 9.0 
Hz, 1H), 7.22 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.16 (s, 1H), 4.85 (d, J = 15.3 Hz, 1H), 4.56 (d, 
J = 9.3 Hz, 1H), 4.09 (s, 3H), 4.04 (s, 3H), 4.00 (s, 3H), 3.76 (d, J = 9.9 Hz, 1H), 3.34-3.17 
(m, 3H), 3.03 (m, 2H), 2.79 (m, 2H), 2.21 (m, 1H), 2.04-1.89 (m, 2H), 1.00-0.98 (s, 6H); ESI 
MS m/z 435.20 (M+H)+.  
(R)-12N-Dimethylamino-12-aza-cryptopleurine (85): light yellow solid; mp 204-
206 °C; [α]23D= 90.0 ° (c 0.86, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.89 (m, 2H), 7.69 (d, J 
= 9.2 Hz, 1H), 7.19 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 7.11 (s, 1H), 4.48 (d, J = 15.2 Hz, 1H), 
4.23 (d, J = 8.0 Hz, 1H), 4.10 (s, 3H), 4.01 (s, 3H), 3.99 (s, 3H), 3.72 (d, J = 15.2 Hz, 1H), 
3.18 (m, 1H), 3.16 (d, J = 8.0 Hz, 1H), 3.07 (dd, J = 16.0 Hz, J = 3.2 Hz, 1H), 2.83-2.77 (m, 
1H), 2.57-2.54 (m, 1H), 2.52 (s, 6H), 2.45 (m, 1H), 2.00-1.96 (m, 1H), 1.81-1.78 (m, 1H); ESI 
MS m/z 422.15 (M+H)+. 
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(R)-12N-2’-Hydroxyethyl-12-aza-cryptopleurine (86): white solid; mp 175-177 °C; 
[α]23D= 112 ° (c 0.16, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.87-7.86 (m, 2H), 7.70 (d, J = 
9.2 Hz, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 7.18 (s, 1H), 4.48 (d, J = 14.8 Hz, 1H), 
4.33 (d, J = 8.8 Hz, 1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.81-3.76 (m, 2H), 3.70 (d, J 
= 15.2 Hz, 1H), 3.30-3.27 (m, 2H), 3.16 (m, 1H), 3.00-2.94 (m, 3H), 2.75-2.66 (m, 2H), 2.00-
1.90 (m, 2H); ESI MS m/z 423.10 (M+H)+. 
(R)-12N-Cyclopropylmethyl-12-aza-cryptopleurine (87): white solid; mp 80-82 °C; 
[α]23D= 82.9 ° (c 0.17, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.90 (d, J = 2.4 Hz, 
1H), 7.79 (d, J = 9.2 Hz, 1H), 7.27 (s, 1H), 7.20 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.39 (d, J = 
15.2 Hz, 1H), 4.24 (d, J = 9.2 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.62 (d, J = 
15.2 Hz, 1H), 3.27-3.24 (m, 1H), 3.13 (dd, J = 16.4 Hz, J = 3.2 Hz, 1H), 2.93 (dd, J = 16.0 
Hz, J = 10.0 Hz, 1H), 2.86 (d, J = 9.2 Hz, 1H), 2.53-2.34 (m, 4H), 1.95-1.89 (m, 2H), 1.00-
0.96 (m, 1H), 0.58-0.54 (m, 2H), 0.19-0.15 (m, 2H); ESI MS m/z 433.20 (M+H)+. 
(S)-12-Oxa-cryptopleurine (88): The aldehyde 77 (100 mg, 0.21 mmol) was 
dissolved in MeOH, to which NaBH4 (19 mg, 0.50 mmol) was added in one portion. The 
mixture was stirred for 1 h and Sat. NaHCO3 was added. After Normal workup, 80 mg white 
solid was obtained, which was used without further purification. The residue was dissolved 
in CH2Cl2 (10 ml), to which MgSO4, K2CO3, and HCHO were added sequentially. The mixture 
was stirred overnight. After normal workup, chromatography gave 32 mg of 88 as a white 
solid. Yield: 40% for two steps; light yellow solid; mp 195-197 °C; [α]23D= -56.8 ° (c 0.60, 
CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89-7.88 (m, 2H), 7.75 (d, J = 9.3 Hz, 1H), 7.22 (s, 
1H), 7.19 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.79 (d, J = 8.4 Hz, 1H), 4.41 (d, J = 15.3 Hz, 1H), 
4.19 (dd, J = 11.1 Hz, J = 5.1 Hz, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.03 (s, 1H), 4.01 (s, 3H), 
3.75-3.65 (m, 2H), 3.17 (dd, J = 15.9 Hz, J = 3.6 Hz, 1H), 2.95-2.80 (m, 2H), 2.06-1.92 (m, 
1H), 1.74 (m, 1H); ESI MS m/z 380.05 (M+H)+. 
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(S)-tert-Butyl-6,7,10-trimethoxy-3-((2-methoxy-2-oxoethylamino)methyl)-3,4-
dihydrodibenzo[f,h]isoquinoline-2(1H)-carboxylate (90): The Boc-aldehyde was obtained 
using the same procedure as compound 46. Glycine methyl ester hydrochloride (314 mg, 
2.5 mmol) and Et3N (0.35 ml, 2.5 mmol) were added to the aldehyde in MeOH (30 ml), 
which was stirred for 0.5 h. Then HOAc (0.70 ml, 12 mmol) and NaBH3CN (165 mg, 2.5 
mmol) were added. The mixture was stirred for 2 h until all the aldehyde disappeared. Sat. 
NaHCO3 was used to quench the reaction and CH2Cl2 was used for extraction, and washed 
with brine, dried over MgSO4. Chromatography gave 635 mg of compound 90 as a white 
solid. Yield: 61% over two steps. mp 78-80 °C; [α]23D= 91.6 ° (c 0.37, CHCl3); 1H NMR (400 
MHz, CDCl3): δ 7.92 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 7.87 (brs, 1H), 7.44-7.42 (m, 2H), 7.29 
(s, 1H), 7.25-7.23 (m, 1H), 5.40-5.29 (m, 1H), 4.92-4.78 (m, 1H), 4.56 (m, 1H), 4.11 (s, 3H), 
4.05 (s, 3H), 4.02 (s, 3H), 3.66 (s, 3H), 3.47-3.36 (m, 2H), 3.27 (dd, J = 16.4 Hz, J = 6.4 Hz, 
1H), 3.14 (d, J = 16.4 Hz, 1H), 2.81 (dd, J = 12.0 Hz, J = 8.8 Hz, 1H), 2.64 (dd, J = 12.0 Hz, 
J = 6.4 Hz, 1H), 1.54 (s, 9H); ESI MS m/z 525.20 (M+H)+. 
(S)-13N-Boc-11-oxo-13-aza-cryptopleurine (91): The ester (635 mg, 1.21 mmol) 
was dissolved in HCl (1.25M in methanol, 15 ml), which was stirred at 50°C for 1 h. The 
solvent was removed. 30 ml of MeOH and Et3N (0.3 ml) were added. The mixture was 
stirred at r.t. for 2 h. After normal workup, chromatography afforded 404 mg of ring-closed 
intermediate as a white solid. Using similar procedure as for compound 45, the intermediate 
was protected by (Boc)2O to give 456 mg of 91 as a white solid. Yield: 76% over three steps. 
mp 125-127 °C; [α]23D= -202.8 ° (c 0.50, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.89 (s, 1H), 
7.88 (d, J = 2.8 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.23 (dd, J = 9.2 Hz, J = 2.8 Hz, 1H), 7.19 
(s, 1H), 5.88 (d, J = 17.2 Hz, 1H), 4.49 (d, J = 17.2 Hz, 1H), 4.40 (d, J = 18.0 Hz, 1H), 4.10 
(s, 4H), 4.05 (s, 4H), 4.01 (s, 3H), 3.87-3.77 (m, 2H), 3.16 (m, 2H), 1.51 (s, 9H); ESI MS m/z 
493.10 (M+H)+, 985.20 (2M+H)+. 
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(S)-13N-Boc-13-aza-cryptopleurine (92): To a solution of the amide (456 mg, 0.93 
mmol) in THF (30 ml) was added BMS (2M in THF, 2.79 ml), which was stirred at r.t. 
overnight. 5 ml of MeOH was added and the mixture was refluxed for 1 h. Chromatography 
afforded 400 mg of 92 as a white solid. Yield: 90%. mp 116-118 °C; [α]23D= -182.5 ° (c 0.28, 
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.88-7.87 (m, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.20 (s, 
1H), 7.19 (dd, J = 8.8 Hz, J = 2.8 Hz, 1H), 4.44 (d, J = 15.2 Hz, 1H), 4.29 (m, 1H), 4.11 (m, 
1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (s, 3H), 3.66  (d, J = 15.2 Hz, 1H), 3.15 (m, 2H), 3.04 
(dd, J = 16.4 Hz, J = 3.2 Hz, 1H), 2.87 (m, 1H), 2.80 (dd, J = 16.4 Hz, J = 11.8 Hz, 1H), 
2.57-2.52 (m, 1H), 2.45 (dt, J = 12.0 Hz, 3.2 Hz, 1H); ESI MS m/z 479.10 (M+H)+. 
General procedures for the synthesis of 13N-substituted-13-aza-cryptopleurine 
(93-109): (a) 13N-Boc-13-aza-cryptopleurine was stirred in HCl/MeOH for 2 h before the 
solvent was removed in vacuum. The solid was collected and washed sequentially with cold 
MeOH and ether. Then the solid was dissolved in 10 ml of anhydrous CH2Cl2 and Et3N (0.1 
ml), to which RCOCl was added at 0 °C. The mixture was stirred at r.t. for 4 h before 1N HCl 
was added. After normal workup, chromatography afforded from light orange to white solids. 
Yield: 70% - 80%. (b) Using the same procedures (reductive amination) as compound 90. 
Yield: 50%- 80%.  
(S)-13-Aza-cryptopleurine dihydrochloride (93): light yellow solid; mp 228 °C 
(dec.); [α]23D= -66.7 ° (c 0.77, DMSO); 1H NMR (400 MHz, free amine, CDCl3): δ 7.89 (s, 1H), 
7.88 (d, J = 2.4 Hz, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.20 (s, 1H), 7.19 (dd, J = 8.8 Hz, J = 2.8 
Hz, 1H), 4.41 (d, J = 15.2 Hz, 1H), 4.17 (d, J = 5.4 Hz, 1H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 
(s, 3H), 3.96 (s, 2H), 3.67 (d, J = 15.2 Hz, 1H), 3.33 (dd, J = 12.0 Hz, J = 2.0 Hz, 1H), 3.20-
3.08 (m, 3H), 3.01 (dd, J = 16.0 Hz, J = 2.8 Hz, 1H), 2.85-2.78 (m, 2H), 2.61-2.48 (m, 2H); 
ESI MS m/z 379.10 (M+H)+. 
(S)-13N-Ethyl-13-aza-cryptopleurine (94): light yellow solid; mp 83-85 °C; [α]23D= -
100.5 ° (c 0.61, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.91 (s, 1H), 7.90 (d, J = 2.7 Hz, 1H), 
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7.79 (d, J = 9.0 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 4.47 (d, J = 14.7 
Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.70 (d, J = 14.7 Hz, 1H), 3.24 (m, 2H), 3.07 
(m, 2H), 2.93-2.84 (m, 2H), 2.71-2.63 (m, 2H), 2.54 (q, J = 7.2 Hz, 2H), 2.39-2.32 (m, 1H), 
2.11 (t, J = 10.5 Hz, 1H), 1.18 (t, J = 6.9 Hz, 3H); ESI MS m/z 407.15 (M+H)+. 
(S)-13N-Methoxycarbonyl-13-aza-cryptopleurine (95): light yellow solid; mp 99-
101 °C; [α]23D= -110.4 ° (c 0.28, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89-7.88 (m, 2H), 
7.75 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 8.7 Hz, J = 2.4 Hz, 1H), 7.19 (s, 1H), 4.44 (d, J = 15.3 
Hz, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.76 (s, 3H), 3.65 (d, J = 15.0 Hz, 1H), 3.30-
3.04 (m, 4H), 3.00-2.77 (m, 3H), 2.62-2.42 (m, 2H); ESI MS m/z 437.10 (M+H)+.  
(S)-13N-Acetyl-13-aza-cryptopleurine (96): light yellow solid; mp 123-125 °C; 
[α]23D= -105.3 ° (c 0.17, CHCl3) ; 1H NMR (300 MHz, CDCl3, rotameric at r.t.): δ 7.90 (t, J = 
3.3 Hz, 2H), 7.79-7.74 (d, J = 9.0 Hz, 1H), 7.23-7.18 (m, 2H), 4.84-4.66 (d, J = 12.6 Hz, 1H), 
4.47 (dd, J = 15.6 Hz, J = 3.0 Hz, 1H), 4.11 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.88-3.48 (m, 
2H), 3.26-2.97 (m, 3H), 2.90-2.70 (m, 2H), 2.58-2.39 (m, 2H), 2.20-2.18 (s, 3H); ESI MS m/z 
421.10 (M+H)+.  
(S)-13N-Methylsulfonyl-13-aza-cryptopleurine (97): light yellow solid; mp 230 °C 
(dec.); [α]23D= -66.9 ° (c 0.16, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.90 (s, 1H), 7.88 (d, J = 
3.0 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.15 (s, 1H), 4.45 
(d, J = 15.6 Hz, 1H), 4.11 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.98 (m, 1H), 3.81 (d, J = 9.0 Hz, 
1H), 3.71 (d, J = 16.2 Hz, 1H), 3.26 (d, J = 11.7 Hz, 1H), 3.14-3.00 (m, 2H), 2.87 (s, 3H), 
2.81-2.60 (m, 4H); ESI MS m/z 457.05 (M+H)+. 
(S)-13N-Methoxycarbonylmethyl-13-aza-cryptopleurine (98): white solid; mp 111-
113 °C; [α]23D= -29.2 ° (c 0.36, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89 (s, 1H), 7.88 (d, J 
= 3.0 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.21-7.17 (m, 2H), 4.44 (d, J = 15.6 Hz, 1H), 4.10 (s, 
3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.77 (s, 3H), 3.70 (d, J = 14.4 Hz, 1H), 3.34 (s, 2H), 3.26 (d, 
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J = 10.8 Hz, 1H), 3.18 (d, J = 11.4 Hz, 1H), 3.04 (m, 2H), 2.88-2.70 (m, 3H), 2.64-2.56 (m, 
1H), 2.36-2.30 (m, 1H); ESI MS m/z 451.15 (M+H)+. 
(S)-13N-Cyclopropylmethyl-13-aza-cryptopleurine (99): white solid; mp 160-
162 °C; [α]23D= -42.6 ° (c 0.34, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.91 (s, 1H), 7.89 (d, J 
= 2.4 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.24 (s, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 
4.48 (d, J = 15.6 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.69 (d, J = 15.6 Hz, 1H), 
3.37 (d, J = 10.2 Hz, 1H), 3.19 (t, J = 13.2 Hz, 2H), 3.15-3.06 (m, 1H), 2.92-2.83 (m, 1H), 
2.78-2.65 (m, 2H), 2.43-2.38 (m, 1H), 2.37 (d, J = 6.6 Hz, 2H), 2.14 (t, J = 10.5 Hz, 1H), 
0.96-0.89 (m, 1H), 0.58 (d, J = 7.8 Hz, 2H), 0.19 (d, J = 5.4 Hz, 2H); ESI MS m/z 433.15 
(M+H)+. 
(S)-13N-Cyclopropyl-13-aza-cryptopleurine (100): white solid; mp 115-117 °C; 
[α]23D= -104.6 ° (c 0.28, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89 (s, 1H), 7.88 (d, J = 2.7 
Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.21 (s, 1H), 7.19 (dd, J = 9.3 Hz, J = 2.7 Hz, 1H), 4.49 (d, 
J = 15.6 Hz, 1H), 4.10 (s, 3H), 4.04 (s, 3H), 4.00 (s, 3H), 3.69 (d, J = 14.4 Hz, 1H), 3.34 (d, J 
= 10.8 Hz, 1H), 3.26-3.18 (m, 1H), 3.13-3.02 (m, 2H), 2.97-2.80 (m, 1H), 2.72-2.57 (m, 3H), 
2.52-2.40 (m, 1H), 1.79-1.72 (m, 1H), 0.54-0.52 (m, 4H); ESI MS m/z 419.10 (M+H)+. 
(S)-13N-Benzoyl-13-aza-cryptopleurine (101): white solid; mp 203 °C (dec.); 
[α]23D= -66.6 ° (c 0.50, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.87 (brs, 2H), 7.72 (brs, 1H), 
7.51-7.45 (m, 5H), 7.19 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.06 (s, 1H), 4.88-4.81 (m, 1H), 
4.44 (m, 1H), 4.09-4.00 (s, 9H), 3.85-3.46 (m, 2H), 3.27-3.08 (m, 3H), 2.85-2.70 (m, 2H), 
2.58-2.41 (m, 2H); ESI MS m/z 483.15 (M+H)+.  
(S)-13N-(2’-Hydroxy)ethyl-13-aza-cryptopleurine (102): light yellow solid; mp 
266 °C (dec.); [α]23D= -56.0 ° (c 0.15, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.90-7.88 (m, 
2H), 7.78 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.19 (s, 1H), 4.46 (d, J = 
15.0 Hz, 1H), 4.10 (s, 3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.71 (t, J = 5.1 Hz, 2H), 3.67 (d, J = 
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14.7 Hz, 1H), 3.21-3.19 (m, 2H), 3.06-2.97 (m, 2H), 2.90-2.81 (m, 1H), 2.65 (t, J = 5.4 Hz, 
2H), 2.62-2.47 (m, 3H), 2.25 (t, J = 10.5 Hz, 1H); ESI MS m/z 423.15 (M+H)+. 
(S)-13N-Dimethoxyphosphoryl-13-aza-cryptopleurine (103): light yellow solid; mp 
98-100 °C; [α]23D= -92.4 ° (c 0.25, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89-7.88 (m, 2H), 
7.76 (d, J = 9.3 Hz, 1H), 7.19 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.18 (s, 1H), 4.44 (d, J = 15.6 
Hz, 1H), 4.09 (s, 3H), 4.04 (s, 3H), 4.01 (s, 3H), 3.77 (d, J = 3.3 Hz, 3H), 3.73 (d, J = 3.0 Hz, 
3H), 3.67 (m, 2H), 3.58 (m, 1H), 3.24-3.13 (m, 2H), 3.06 (dd, J = 16.2 Hz, J = 3.3 Hz, 1H), 
2.94-2.75 (m, 2H), 2.62-2.46 (m, 2H); ESI MS m/z 487.15 (M+H)+. 
(S)-13N-Methyl-13-aza-cryptopleurine (104): white solid; mp 179-181 °C; [α]23D= -
112.2 ° (c 0.3, CHCl3) ; 1H NMR (400 MHz, CDCl3): δ 7.87-7.86 (m, 2H), 7.74 (d, J = 9.2 Hz, 
1H), 7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 7.16 (s, 1H), 4.45 (d, J = 15.3 Hz, 1H), 4.10 (s, 
3H), 4.06 (s, 3H), 4.01 (s, 3H), 3.90 (m, 1H), 3.75-3.65 (m, 1H), 3.68 (d, J = 15.6 Hz, 1H), 
3.26-3.15 (m, 2H), 3.09-3.04 (m, 1H), 2.95-2.85 (m, 2H), 2.90 (s, 6H), 2.67-2.55 (m, 2H); 
ESI MS m/z 450.15 (M+H)+. 
(S)-13N-Benzyl-13-aza-cryptopleurine (105): white solid; mp 94-96 °C; [α]23D= -
177 ° (c 0.21, CHCl3) ; 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1H), 7.89 (d, J = 2.8 Hz, 1H), 
7.79 (d, J = 9.2 Hz, 1H), 7.42-7.34 (m, 4H), 7.31-7.29 (m, 1H), 7.20 (s, 1H), 7.19 (dd, J = 8.8 
Hz, J = 2.4 Hz, 1H), 4.47 (d, J = 15.3 Hz, 1H), 4.09 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H), 3.70 
(d, J = 14.8 Hz, 1H), 3.66 (d, J = 12.8 Hz, 1H), 3.57 (d, J = 13.2 Hz, 1H), 3.20-3.13 (m, 2H), 
3.04-2.97 (m, 2H), 2.88-2.81 (m, 1H), 2.72-2.63 (m, 2H), 2.45 (dt, J = 11.2 Hz, J = 2.4 Hz, 
1H), 2.14 (t, J = 10.4 Hz, 1H); ESI MS m/z 469.20 (M+H)+. 
(R)-13N-Dimethylcarbamyl-13-aza-cryptopleurine (106): yellow solid; mp 206-
208 °C; [α]23D= 139 ° (c 0.3, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.89-7.88 (m, 2H), 7.76 
(d, J = 9.0 Hz, 1H), 7.21 (s, 1H), 7.19 (dd, J = 9.0 Hz, J = 2.1 Hz, 1H), 4.46 (d, J = 15.6 Hz, 
1H), 4.09 (s, 3H), 4.03 (s, 3H), 4.00 (s, 3H), 3.71 (d, J = 15.2 Hz, 1H), 3.34 (d, J = 11.2 Hz, 
1H), 3.23 (d, J = 11.2 Hz, 1H), 3.15 (d, J = 10.8 Hz, 1H), 3.08-3.05 (m, 1H), 2.85-2.82 (m, 
89 
2H), 2.76 (dt, J = 12.0 Hz, J = 2.4 Hz, 1H), 2.61 (dt, J = 12.0 Hz, J = 2.4 Hz, 1H), 2.56 (s, 
3H), 2.37-2.32 (m, 1H); ESI MS m/z 393.10 (M+H)+. 
(R)-13N-Isobutyl-13-aza-cryptopleurine (107): white solid; mp 175-177 °C; [α]23D= 
98.2 ° (c 1.1, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.87-7.86 (m, 2H), 7.74 (d, J = 9.0 Hz, 
1H), 7.20 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 7.18 (s, 1H), 4.53 (d, J = 15.3 Hz, 1H), 4.10 (s, 
3H), 4.05 (s, 3H), 4.01 (s, 3H), 3.80 (m, 1H), 3.37-3.28 (m, 2H), 3.18-3.09 (m, 2H), 2.95-2.86 
(m, 2H), 2.63-2.60 (m, 2H), 2.42 (d, J = 6.6 Hz, 2H), 2.41 (m, 1H), 1.98 (m, 1H), 1.01 (s, 3H), 
0.99 (s, 3H); ESI MS m/z 435.10 (M+H)+. 
(R)-13N-Benzyl-13-aza-cryptopleurine (108): white solid; mp 86-88 °C; [α]23D= 
31.9 ° (c 3.3, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.87 (s, 2H), 7.76 (d, J = 9.0 Hz, 1H), 
7.42-7.30 (m, 5H), 7.18 (dd, J = 9.6 Hz, J = 2.4 Hz, 1H), 7.15 (s, 1H), 4.45 (d, J = 15.3 Hz, 
1H), 4.08 (s, 3H), 4.01 (s, 3H), 4.00 (s, 3H), 3.70 (d, J = 16.5 Hz, 1H), 3.67 (d, J = 12.9 Hz, 
1H), 3.56 (d, J = 12.9 Hz, 1H), 3.21-3.12 (m, 2H), 3.00-2.96 (m, 2H), 2.87-2.78 (m, 1H), 
2.70-2.63 (m, 2H), 2.49-2.42 (m, 1H), 2.14 (t, J = 10.2 Hz, 1H); ESI MS m/z 469.15 (M+H)+. 
(R)-13N-Cyclopropylmethyl-13-aza-cryptopleurine (109): white solid; mp 156-
158 °C; [α]23D= 50 ° (c 0.72, CHCl3) ; 1H NMR (400 MHz, CDCl3): δ 7.73 (s, 2H), 7.59 (d, J = 
8.8 Hz, 1H), 7.15 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 7.04 (s, 1H), 4.36 (brs, 1H), 4.06 (s, 3H), 
4.03 (s, 3H), 4.00 (s, 3H), 3.95 (brs, 1H), 3.68-3.60 (m, 2H), 3.26 (brs, 1H), 3.13-2.86 (m, 
6H), 2.67 (m, 2H), 1.15 (m, 1H), 0.80 (m, 2H), 0.42 (m, 2H); ESI MS m/z 433.15 (M+H)+. 
(S)-13-Oxa-cryptopleurine (110): Compound 44 (177 mg, 0.5 mmol) was 
suspended in dry CH2Cl2 (15 ml) and Et3N (0.14 ml, 1.00 mmol) at 0 °C, to which 
chloroacetyl chloride (40 μl, 0.50 mmol) in 1 ml of CH2Cl2 was added dropwise slowly. The 
mixture was stirred at 0 °C for 5 h before 1N HCl was added. The organic layer was 
separated and washed with sat. NaHCO3 and brine, dried over MgSO4. CH2Cl2 was removed 
and the residue was dissolved in anhydrous THF (5 ml), to which NaH (2.1 equiv.) was 
added at r.t. followed by reflux for 2 h. Sat. NH4Cl was added and CH2Cl2 was used for 
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extraction. After workup, the organic layer was dried over MgSO4. Then the residue was 
dissolved in 10 ml anhydrous THF, BMS (1.50 ml, 6 mmol) was added, which was stirred at 
r.t. overnight. MeOH (5 ml) was added and the mixture was refluxed for 1 h. 
Chromatography gave 73 mg of 110 as a white solid. Yield: 38.5% for three steps; white 
solid; mp 199-201 °C; [α]23D= -134.6 ° (c 0.52, CHCl3) ; 1H NMR (300 MHz, CDCl3): δ 7.86-
7.85 (m, 2H), 7.74 (d, J = 9.0 Hz, 1H), 7.18 (dd, J = 9.0 Hz, J = 2.4 Hz, 1H), 7.14 (s, 1H), 
4.39 (d, J = 15.6 Hz, 1H), 4.12 (m, 2H), 4.08 (s, 3H), 4.03 (s, 3H), 4.00 (s, 3H), 3.91-3.83 (m, 
1H), 3.66 (d, J = 15.6 Hz, 1H), 3.51 (dd, J = 11.1 Hz, J = 9.0 Hz, 1H), 3.06 (d, J = 11.7 Hz, 
1H), 2.91-2.87 (m, 1H), 2.76-2.59 (m, 3H); ESI MS m/z 380.05 (M+H)+. 
(S)-13-Oxa-E7 (112): The aldehyde 77 (140 mg, 0.30 mmol) was dissolved in MeOH, 
to which NaBH4 (76 mg, 2 mmol) was added. The resulting mixture was stirred at r.t. for 1 h 
before sat. NaHCO3 was added. The mixture was extracted with CH2Cl2 and the organic 
layers were combined, washed with brine, and dried over Na2SO4. Then the solvent was 
removed under reduced pressure and redissolved in TFA/CH2Cl2 (1:1, 10 mL), which was 
stirred for 0.5 h. The mixture was concentrated to remove TFA. The residue was subject to 
treatment with chloroacetyl chloride and the rest of the synthesis was similar as that of 
compound 110. After chromatography, 37 mg of 112 was obtained as a light yellow solid in 
24% yield over five steps. mp 183-185 °C; [α]23D= -114.7 ° (c 0.19, CHCl3) ; 1H NMR (400 
MHz, CDCl3): δ 7.90 (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.24 (s, 1H), 
7.19 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 4.43 (d, J = 15.2 Hz, 1H), 4.10 (s, 3H), 4.05 (m, 4H), 
4.01 (m, 4H), 3.98-3.90 (m, 3H), 3.20-3.13 (m, 1H), 3.08-3.01 (m, 3H), 2.96-2.91 (m, 1H), 
2.25-2.19 (m, 1H), 2.17-2.11 (m, 1H); ESI MS m/z 394.10 (M+H)+. 
 
4.7.2.  Biological assay – In vitro cell growth inhibition assay 
The sulforhodamine B assay was used according to the procedures developed and 
validated at NCI. The in vitro anticancer activities are expressed as IC50 values, which is the 
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test compound concentration (μg/mL) that reduced the cell number by 50% after 72 h of 
treatment. The values were interpolated from dose-response data. Each test was performed 
in triplicate with a variation of less than 5%. The IC50 values determined in each of the 
independent tests varied less than 10%. Compound stock solutions were prepared in DMSO 
with the final solvent concentration ≤1% DMSO (v/v), a concentration without effect on cell 
replication. The cells were cultured at 37 °C in RPMI-1640 supplemented with 25 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 2% (w/v) sodium bicarbonate, 
10% (v/v) fetal bovine serum, and 100 μg/mL kanamycin in a humidified atmosphere 
containing 5% CO2. 
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CHAPTER 5 
BIOLOGICAL STUDIES OF NEW PBT DERIVATIVES AND ANTOFINE & 
CRYPTOPLEURINE ANALOGS 
 
5.1 Mechanistic studies of new PBT derivatives  
5.1.1  Introduction 
In addition to the cell growth inhibition assay using five cancer cell lines, assays were 
also performed in order to better understand how these new PBT analogs kill cancer cells. 
Prior studies showed that PBT analogs inhibited cancer cell growth through the Akt and NF-
κB signaling pathways; thus, 19 new PBT analogs were also studied in the same assays.1  
 
5.1.2 Methodology 
NF-κB Luciferase Assay. Cells were cultured in 12-well plates and transiently 
cotransfected with 0.2 μg of a pNF-κB-Luc vector (Stratagene, La Jolla, CA) and 0.2 μg of 
pSV-β-galactosidase dissolved in 3 μL lipofectamine or lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) as the internal control. The plasmids were transfected according to the 
manufacturer’s instructions. After 6 h, the medium was changed to complete medium and 
cultured for 6 h, and then the transfected cells were treated with different compounds in 
complete medium for 24 h. Cell extracts were harvested using 150 μL of lysis buffer (Tropix, 
Inc., Bedford, MA) per well. To measure the luciferase and β-galactosidase activities, cell 
extracts (20 μL each) were assayed separately using the Luciferase Assay Kit and Galacto-
Light Plus system (Tropix, Inc.), respectively. Luciferase activity was measured and 
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analyzed using an FB12 luminometer (Zylux Corporation, Oak Ridge, TN).   
Western Blot Analysis. Cells were treated with different compounds for 48 h. Equal 
amounts (50 μg) of cell lysate were separated by 10% SDS-PAGE and transferred to 
polyvinylidene membrane (Millipore, Billerica, MA). The membrane was probed with 
antibodies directed against p-Akt, Akt, and β-actin (Sigma, St. Louis, MO). Antibodies were 
diluted in TBS (pH 7.5) containing 0.05% (v/v) Tween 20, and 5% (w/v) dried milk. Blots 
were incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibodies (Amersham Biosciences, Uppsala, Sweden). Bound antibodies were visualized 
by electrochemical luminescence staining with autoradiographic detection using Kodak X-
Omat Blue film (PerkinElmer Life Science, Boston, MA) or Typhoon9410 variable mode 
imager (Amersham BioScience, Piscataway, NJ). 
 
5.1.3  Results and discussion 
 
 
Figure 5-1 Inhibitory effects of PBT analogs on Akt and its phosphorylaiton  
in A549 (upper) and CL1-0 cells (lower) 
As shown in Figure 5-1, the 19 newly synthesized compounds were examined for 
effects on Akt activation in A549 and CL1-0 cells. Four compounds, 13 (YXM35), 19 
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(YXM41), 21 (YXM43), and 22 (YXM44), which were equipotent or more potent than to PBT-
1 against the tested tumor cell lines, consistently showed greater suppression of Akt 
activation than PBT-1 in both lung cancer cell lines, especially in decreasing Akt protein 
phosphorylation. Further assays are still needed to distinguish whether the inhibitory activity 
on Akt is due to transcriptional inhibition or protein stability.  
In addition, when evaluated for effects on the NF-κB signaling pathway, the four 
compounds also showed more potent suppression of NF-κB activity than PBT-1, parallel to 
the results in our cell-based cytotoxicity testing. These results suggest that these 
compounds may stop tumor cell growth through inhibition of both Akt activation and NF-κB 
related signaling pathways (Figure 5-2).  
 
 
 
Figure 5-2 Inhibitory effects of PBT analogs on NF-κB signaling pathway in A549 (upper) and CL1-0 
cells (lower) 
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5.2  In vivo test of compound 110 (YXM74) 
5.2.1  Introduction 
To further evaluate the efficacy of compound YXM74, it was tested against HT-29 
human colorectal adenocarcinoma xenograft, which is collaborated with Dr. Che-Ming 
Teng’s lab at National Taiwan University. 
 
5.2.2 Methodology 
Mice 
Male nude-athymic mice (NTUH Animal Facility) were 8 weeks old, and had a body 
weight (BW) range of 16.0-21.2 g, on D1 of the study. The animals were fed ad libitum water 
(reverse osmosis, 1 ppm Cl) and PicoLab Rodent Diet 20 Modified and Irradiated Lab Diet® 
consisting of 20.0% crude protein, 9.9% crude fat, and 4.7% crude fiber. The mice were 
housed on National Taiwan University Laboratory Animal Center, NTUMC, on a 12-hour 
light cycle at 21-23 °C and 60-85% humidity. Nude-Athymic mice were maintained in 
accordance with the Institutional Animal Care and Use Committee procedures and 
guidelines. 
Tumor Cell Culture 
Human HT-29 colorectal adenocarcinoma cells were maintained in RPMI 1640 
medium containing 100 units/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, 0.25 
μg/mL amphotericin B, and 25 μg/mL gentamicin. The medium was supplemented with 10% 
heat-inactivated fetal bovine serum and 2 mM glutamine. The cells were cultured in tissue 
culture flasks in a humidified incubator at 37 °C, in an atmosphere of 5% CO2 and 95% air. 
In Vivo Implantation and Tumor Growth 
The human HT-29 colorectal adenocarcinoma cells used for implantation were 
harvested during log phase growth and resuspended in phosphate-buffered saline at 5×107 
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cells/mL. Each mouse was injected s.c. in the right flank with 1×107 cells (0.2 mL cell 
suspension). Tumors were monitored twice weekly and then daily as their volumes 
approached 50 mm3. On day 1 of the study, the animals were sorted into treatment groups 
with tumor sizes of 24.8-121.8 mm3 and group mean tumor sizes of ~112.1 mm3. Tumor size, 
in mm3, was calculated from: 
 
where w = width and l = length in mm of the tumor. Tumor weight can be estimated with the 
assumption that 1 mg is equivalent to 1 mm3 of tumor volume. 
Time to Endpoint (TTE) and Tumor Growth Delay (TGD) 
Each animal was euthanized when the tumors reached the predetermined endpoint 
size of 1200 mm3. The time to endpoint (TTE) for each mouse was calculated by the 
following equation: 
 
where TTE is expressed in days, endpoint volume is in mm3, b is the intercept, and m is the 
slope of the line obtained by linear regression of a log-transformed tumor growth data set. 
The data set is comprised of the first observation that exceeded the study endpoint volume 
and the three consecutive observations that immediately preceded the attainment of the 
endpoint volume. The calculated TTE is usually less than the day on which an animal is 
euthanized for tumor size. Animals that do not reach the endpoint are euthanized at the end 
of the study, and assigned a TTE value equal to the last day (29 days). An animal classified 
as having died from treatment-related (TR) causes or nontreatment-related metastasis 
(NTRm) causes is assigned a TTE value equal to the day of death. An animal classified as 
having died from non-treatment-related (NTR) causes is excluded from TTE calculations. 
Treatment efficacy was determined from tumor growth delay (TGD), which is defined as the 
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increase in the median TTE for a treatment group compared to the control group:  
 
expressed in days, or as a percentage of the median TTE of the control group: 
 
 
where: 
T = median TTE for a treatment group, 
C = median TTE for control Group 1. 
 
5.2.3  Results and discussion 
Group 1 mice received vehicle and served as the control for all treatment groups. All 
tumors in the eight mice grew to the 1200 mm3 endpoint volume. The median TTE for mice 
in the control group was 16.3 days with a range of 13.8-21.9 days. YXM74, i.v. at 20 mg/kg 
qd to end, produced a median TTE of 21.3 days corresponding to a 5-day T–C and a %TGD 
of 31. Based on the logrank analysis, YXM74 produced significant antitumor activity (P < 
0.05). YXM74, i.v./i.p. at 20 mg/kg bid to end, produced a median TTE of 20.9 days 
corresponding to a 4.6-day T–C and a %TGD of 28. Based on the logrank analysis, YXM74 
produced significant antitumor activity (P < 0.05). One tumor remained in the study on day 
29 (Figure 5-3). 
YXM74, i.v. at 20 mg/kg qd, caused a significant 1.1% maximum group body weight 
loss occurring on day 12. YXM74, i.v./i.p. at 20 mg/kg bid, caused a significant 7.2% 
maximum group body weight loss occurring on day 19. One TR death occurred on day 20 
(Figure 5-3, red box).  In summary, YXM74, at a dose of 20 mg/kg, exhibited significant 
antitumor activity against HT-29 human colorectal adenocarcinoma in male nude-athymic 
mice. When dosing frequency was increased, the toxicity also increased without producing 
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better antitumor efficacy (Figure 5-4). 
 
 
Figure 5-3 Individual TTE for mice in HT-29 study 
 
 
Figure 5-4 In vivo anticancer activity of YXM74 (compound 110) 
 
These data demonstrated that YXM74 displayed potent anticancer activity in vitro as 
well as significant tumor growth inhibition in vivo at a dose of 20 mg/kg without causing 
101 
obvious toxicity. However, it will still be tested in other animal tumor models to determine 
which type of tumor(s) is the most sensitive. Moreover, its CNS toxicity will be investigated in 
the future for more direct evidence.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
6.1  Conclusions 
Through all of these efforts, we have obtained a number of active analogs that have 
both strong in vitro anticancer activity and potentially reduced CNS toxicity as predicted by 
the BBB penetration ratio.  In the PBT series, four compounds (13, 19, 21, and 22) were 
confirmed to possess comparable or higher potency than PBT-1 with strong inhibition of Akt 
phosporylation and NF-κB signaling. A new synthetic strategy was established that is able to 
provide analogs with various E-ring modifications, by which polar moieties can be introduced 
leading to potentially reduced CNS toxicity. With an ample supply of the intermediate 44 in 
hand, several new analogs with a heteroatom incorporated in the E-ring were designed, 
synthesized and tested in vitro. Compounds 110 and 112 retained strong anticancer activity, 
in addition to improved selectivity against A549 and HCT-8 cancer cell lines. In vivo study 
demonstrated that YXM74 had significant tumor growth inhibition at a dose of 20 mg/kg 
using the xenograft model of HT-29 human colorectal adenocarcinoma. 
 
6.2  Design, synthesis and SAR study of new PBT analogs 
6.2.1  Design  
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Figure 6-1 Proposed new PBT analogs 
 
Future development of PBT analogs (Figure 6-1) will be focused on the following aspects: 
1. The effect of ring size will be investigated by synthesizing derivatives with 4-, 5-, 6-, 
and 7-membered side-chain rings along with various representative substitutents. 
2. The C3’ position will be studied intensively, since SAR at this position was not well 
addressed in previous studies. 
3. Heteroatoms will be incorporated into the side-chain ring to study the effect of this 
change on efficacy. 
4. Multiple substituents will be incorporated, so that positive accumulative effects on 
potency might be observed. 
5. The substitution pattern on the phenanthrene ring will be studied as well for more 
detailed SAR results. 
  
6.2.2  Methods 
For the synthesis of these future analogs, the same published strategy will be used.1 
The phenanthrene scaffold will be connected with the N-containing ring (commercially 
available or synthetic) by nucleophilic substitution or formation of amide followed by 
reduction. The obtained derivatives will be tested against four cancer cell lines to determine 
their in vitro anticancer activity and subjected to mechanistic studies in collaboration with Dr. 
Kenneth F. Bastow’s laboratory at UNC-Chapel Hill, and with Dr. Pan-Chyr Yang’s and Dr. 
Che-Ming Teng’s laboratories at National Taiwan University. Assays such as Western Blot, 
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NF-κB luciferase assay, and DNA microarray analysis, as well as in vivo testing etc. will be 
applied in these proposed studies. 
 
6.3  Design, synthesis, and SAR study of new polar antofine and cryptopleurine 
analogs 
6.3.1  Design 
Besides the incorporation of heteroatoms (N or O) in the E-ring of antofine and 
cryptopleurine, another common approach to enhance the polarity of molecules is direct 
introduction of polar substituents, including hydroxy, amino, and other hydrophilic 
functionalities. As discussed in Chapter 4, previously reported synthetic methodologies 
could not accommodate such structural modifications except hydroxylation at C14 (or C15) 
position of antofine (or cryptopleurine). However, with our versatile intermediate 44, analogs 
containing polar substituents at different positions on the E-ring could be prepared. Most 
importantly, by studying substitutions on the E-ring, corresponding SAR could be clarified for 
the first time (Figure 6-2). Another focus will be the investigation of anticancer activity using 
tylophorine as a new starting point, primarily because it has a much better toxicity profile 
than antofine and cryptopleurine in animal tests.  
 
 
Figure 6-2 Proposed new antofine, cryptopleurine, and tylophorine analogs with polar substitutions 
 
6.3.2  Methods 
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6.3.2.1 New polar antofine analogs 
The synthesis of (13aS,13S)-13-hydroxy-antofine (114a) and (13aS,13R)-13-hydroxy-
antofine (114b) is proposed as follows (Scheme 6-1): 
 
Scheme 6-1. Reagents and conditions: (a) i) Py•SO3, DMSO, Et3N, CH2Cl2; ii) LiHMDs, EtOAc, -
78 °C, THF; iii) TFA, CH2Cl2; iv) Et3N, MeOH, reflux (b) BMS, THF 
 
The hydroxy group of 45 is oxidized to an aldehyde, which then undergoes Aldol 
condensation using LiHMDs at -78 °C. The obtained diastereomers are subjected to 
intramolecular cyclization after removal of the Boc group to give a mixture of 113a/b. Lastly, 
the cylic amides are reduced to amines 114a and 114b using BMS in THF. The 
configurations of 114a, 114b, and all following proposed analogs will be determined by 
NOESY techniques. 
For the synthesis of (13aS,12R)-13-hydroxy-antofine (115a) and (13aS,12S)-13-
hydroxy-antofine (115b),  the following synthetic pathway is proposed (Scheme 6-2). The 
ketone 54 is reduced with NaBH4 to give 115a and 115b. The carbonyl group can also be 
transformed into various polar groups via commonly used organic chemistry. 
 
Scheme 6-2. Reagents and conditions: (a) NaBH4, MeOH, r.t. 
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6.3.2.2 New polar cryptopleurine analogs 
One important reason that cryptopleurine analogs are more intriguing for study is the 
fact that, among the natural alkaloids in NCI screening studies, cryptopleurine was the most 
active in the inhibition of cancer cell growth (IC50 = 10-12 M). Given such strong potency in 
the pM range, a suitable balance between activity and CNS toxicity could be easier to 
accomplish, i.e., considerably high activity could be retained with an appropriate toxicity 
profile, even if the potency might decrease by 1000-fold through structural modifications.  
 
Scheme 6-3. Reagents and conditions: (a) i) vinylmagnesium bromide, THF, 0 °C; ii) Dess-Martin 
reagent, CH2Cl2 (b) i) TFA, CH2Cl2; ii) Cs2CO3, MeOH, reflux (c) NaBH4, MeOH 
 
A proposed synthesis of compounds 118a and 118b is shown in Scheme 6-3. 
Compound 77 is treated with vinylmagnesium bromide followed by oxidization using Dess-
Martin periodine to furnish ketone 116. After removal of Boc, intramolecular Michael addition 
occurs to close the E-ring to give 117. In the final step, the carbonyl is reduced by reaction 
with NaBH4 to afford the final products (14aS,13S)-13-hydroxy-cryptopleurine (118a) and 
(14aS,13R)-13-hydroxy-cryptopleurine (118b).  
Additionally, the synthesis of (14aR,12R)-12-hydroxy-cryptopleurine (124a) and 
(14aR,12S)-12-hydroxy-cryptopleurine (124b) is proposed in Scheme 6-4. The carbonyl of 
77 is converted to a vinyl group in 119 using Ph3P=CH2Br. After the Boc protecting group is 
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removed, subsequent condensation with 2-methoxyacrylic acid gives compound 120. Ring 
closing metathesis occurs using the 2nd generation Grubb’s catalyst to afford 121. The cyclic 
amide is then reduced and rearrangement takes place under acidic conditions to give ketone 
123. Reduction with NaBH4 is used to afford the final products 124a and 124b. 
 
Scheme 6-4. Reagents and conditions: (a) Ph3P=CH2Br, n-BuLi, THF (b) i) TFA, CH2Cl2; ii) 2-
methoxyacrylic acid, EDC, HOBt, DMF (c) Grubb's 2nd generation catalyst, CH2Cl2, reflux (d) LiAlH4, 
CeCl3, THF (e) HCl, THF, reflux (f) NaBH4, MeOH 
 
Scheme 6-5. Reagents and conditions: (a) Ph3P=CH2CO2Et, THF (b) i) OsO4, NMO, acetone/H2O 8/1, 
overnight; ii) TFA, CH2Cl2; iii) TEA, MeOH, reflux (c) BMS, THF 
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Moreover, a synthetic route to multiple hydroxylations on the E-ring is also proposed 
(Scheme 6-5).  Compound 77 is converted to E-alkene 125 via a Wittig reaction. Then the 
double bond is dihydroxylated using OsO4 and NMO, and the E-ring is closed after removal 
of Boc by TFA to afford a mixture of trans-diol 126a/b. Finally, the amide is reduced by using 
BMS to give compounds 127a and 127b.  
 
6.3.2.3 New polar E7 analogs 
Given the unexpected and interesting specificity for different cancer cells of 
compound E7, its continued structural modification will be another focus including direct 
introduction of hydroxy, amino, and other polar substituents. 
For example, compound 77 is reacted with methyl propiolate under LiHMDs at -78 °C 
to give alcohol 128. The alkyne is reduced by H2 and Pd/C to afford 129. Ring closure is 
carried out in MeOH and TEA after removal of the protecting group to furnish a mixture of 
130a/b. Finally, two diastereomers 131a and 131b will be obtained by reduction of the 
amide by BMS (Scheme 6-6).  
 
Scheme 6-6. Reagents and conditions: (a) LiHMDs, methyl propiolate, THF, -78 °C (b) H2, Pd/C, 
MeOH (c) i) TFA, CH2Cl2; ii) TEA, MeOH, reflux (d) BMS, THF 
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C13 substituted analogs, such as compound 137a and 137b, will be synthesized as 
shown in Scheme 6-7. The hydroxy group in 45 is converted to an α,β-unsaturated ester in 
132 by oxidation to an aldehyde followed by a Wittig reaction. The alkene is reduced to give 
133 under hydrogenation. Then the ester group is reduced to aldehyde (134) by DIBAL at -
78 °C followed by nucleophilic attack by reacting with ethyl acetate using LiHMDs at low 
temperature to afford 135. The E-ring is closed to give a mixture of diastereomers 136a/b 
that is reduced to give the final products 137a and 137b. 
 
Scheme 6-7. Reagents and conditions: (a) i) Py·SO3, DMSO, CH2Cl2; ii) Ph3P=CH2CO2Et, CH2Cl2 (b) 
H2, Pd/C, MeOH (c) DIBAL, THF, -78 °C (d) EtOAc, LiHMDs, THF, -78 °C (e) i) TFA, CH2Cl2; ii) TEA, 
MeOH, reflux (f) BMS, THF 
 
In summary, with an adequate quantity of the important intermediate 44 in hand, a 
variety of modifications can be carried out, which could not be accomplished through the 
other reported synthetic methodologies. These modifications are also applicable to 
corresponding enantiomers and other alkaloids in this family, including tylophorine and 
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ficuseptine, etc. The obtained analogs will be evaluated in both in vitro and in vivo assays to 
determine their pharmacological effects and possible mechanism(s) of action, and results 
will be reported in due time. 
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